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A B S T R A C T
Background
Accurate and rapid tests for tuberculosis (TB) drug resistance are critical for improving patient care and decreasing the transmission
of drug-resistant TB. Genotype®MTBDRsl (MTBDRsl) is the only commercially-available molecular test for detecting resistance in
TB to the fluoroquinolones (FQs; ofloxacin, moxifloxacin and levofloxacin) and the second-line injectable drugs (SLIDs; amikacin,
kanamycin and capreomycin), which are used to treat patients with multidrug-resistant (MDR-)TB.
Objectives
To obtain summary estimates of the diagnostic accuracy of MTBDRsl for FQ resistance, SLID resistance and extensively drug-resistant
TB (XDR-TB; defined as MDR-TB plus resistance to a FQ and a SLID) when performed (1) indirectly (ie on culture isolates confirmed
as TB positive) and (2) directly (ie on smear-positive sputum specimens).
To compare summary estimates of the diagnostic accuracy of MTBDRsl for FQ resistance, SLID resistance and XDR-TB by type of
testing (indirect versus direct testing).
The populations of interest were adults with drug-susceptible TB or drug-resistant TB. The settings of interest were intermediate and
central laboratories.
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Search methods
We searched the following databases without any language restriction up to 30 January 2014: Cochrane Infectious Diseases Group
Specialized Register; MEDLINE; EMBASE; ISI Web of Knowledge; MEDION; LILACS; BIOSIS; SCOPUS; the metaRegister of
Controlled Trials; the search portal of the World Health Organization International Clinical Trials Registry Platform; and ProQuest
Dissertations & Theses A&I.
Selection criteria
We included all studies that determined MTBDRsl accuracy against a defined reference standard (culture-based drug susceptibility
testing (DST), genetic testing or both). We included cross-sectional and diagnostic case-control studies. We excluded unpublished data
and conference proceedings.
Data collection and analysis
For each study, two review authors independently extracted data using a standardized form and assessed study quality using the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. We performed meta-analyses to estimate the pooled sensitivity and
specificity of MTBDRsl for FQ resistance, SLID resistance, and XDR-TB. We explored the influence of different reference standards.
We performed the majority of analyses using a bivariate random-effects model against culture-based DST as the reference standard.
Main results
We included 21 unique studies: 14 studies reported the accuracy of MTBDRsl when done directly, five studies when done indirectly
and two studies that did both. Of the 21 studies, 15 studies (71%) were cross-sectional and 11 studies (58%) were located in low-
income or middle-income countries. All studies but two were written in English. Nine (43%) of the 21 included studies had a high
risk of bias for patient selection. At least half of the studies had low risk of bias for the other QUADAS-2 domains.
As a test for FQ resistance measured against culture-based DST, the pooled sensitivity of MTBDRsl when performed indirectly was
83.1% (95% confidence interval (CI) 78.7% to 86.7%) and the pooled specificity was 97.7% (95% CI 94.3% to 99.1%), respectively
(16 studies, 1766 participants; 610 confirmed cases of FQ-resistant TB; moderate quality evidence).When performed directly, the pooled
sensitivity was 85.1% (95% CI 71.9% to 92.7%) and the pooled specificity was 98.2% (95% CI 96.8% to 99.0%), respectively (seven
studies, 1033 participants; 230 confirmed cases of FQ-resistant TB; moderate quality evidence). For indirect testing for FQ resistance,
four (0.2%) of 1766MTBDRsl results were indeterminate, whereas for direct testing 20 (1.9%) of 1033 were MTBDRsl indeterminate
(P < 0.001).
As a test for SLID resistance measured against culture-based DST, the pooled sensitivity of MTBDRsl when performed indirectly was
76.9% (95% CI 61.1% to 87.6%) and the pooled specificity was 99.5% (95% CI 97.1% to 99.9%), respectively (14 studies, 1637
participants; 414 confirmed cases of SLID-resistant TB; moderate quality evidence). For amikacin resistance, the pooled sensitivity and
specificity were 87.9% (95% CI 82.1% to 92.0%) and 99.5% (95% CI 97.5% to 99.9%), respectively. For kanamycin resistance, the
pooled sensitivity and specificity were 66.9% (95% CI 44.1% to 83.8%) and 98.6% (95% CI 96.1% to 99.5%), respectively. For
capreomycin resistance, the pooled sensitivity and specificity were 79.5% (95% CI 58.3% to 91.4%) and 95.8% (95% CI 93.4% to
97.3%), respectively. When performed directly, the pooled sensitivity for SLID resistance was 94.4% (95% CI 25.2% to 99.9%) and
the pooled specificity was 98.2% (95% CI 88.9% to 99.7%), respectively (six studies, 947 participants; 207 confirmed cases of SLID-
resistant TB, 740 SLID susceptible cases of TB; very low quality evidence). For indirect testing for SLID resistance, three (0.4%) of 774
MTBDRsl results were indeterminate, whereas for direct testing 53 (6.1%) of 873 were MTBDRsl indeterminate (P < 0.001).
As a test for XDR-TB measured against culture-based DST, the pooled sensitivity of MTBDRsl when performed indirectly was 70.9%
(95%CI 42.9% to 88.8%) and the pooled specificity was 98.8% (95%CI 96.1% to 99.6%), respectively (eight studies, 880 participants;
173 confirmed cases of XDR-TB; low quality evidence).
Authors’ conclusions
In adults with TB, a positive MTBDRsl result for FQ resistance, SLID resistance, or XDR-TB can be treated with confidence. However,
MTBDRsl does not detect approximately one in five cases of FQ-resistant TB, and does not detect approximately one in four cases of
SLID-resistant TB. Of the three SLIDs, MTBDRsl has the poorest sensitivity for kanamycin resistance. MTBDRsl will miss between
one in four and one in three cases of XDR-TB. The diagnostic accuracy of MTBDRsl is similar when done using either culture isolates
or smear-positive sputum. As the location of the resistance causing mutations can vary on a strain-by-strain basis, further research is
required on test accuracy in different settings and, if genetic sequencing is used as a reference standard, it should examine all resistance-
determining regions. Given the confidence one can have in a positive result, and the ability of the test to provide results within a matter
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of days, MTBDRsl may be used as an initial test for second-line drug resistance. However, when the test reports a negative result,
clinicians may still wish to carry out conventional testing.
P L A I N L A N G U A G E S U M M A R Y
The rapid test GenoType® MTBDRsl for testing resistance to second-line TB drugs
Background
Different drugs are available to treat people with tuberculosis (TB), but resistance to these drugs is a growing problem. People with
drug-resistant TB are more likely to die than people with drug-susceptible TB. People with drug-resistant TB require “second-line”
TB drugs that, compared with “first-line” TB drugs used to treat drug-susceptible TB, cause more side effects and must be taken for
longer. Extensively drug-resistant TB (XDR-TB) is a type of TB that is resistant to almost all TB drugs. A rapid and accurate test could
identify people with drug-resistant TB, likely improve patient care, and reduce the spread of drug-resistant TB.
Test evaluated by this review
GenoType® MTBDRsl (MTBDRsl) is the only rapid test that detects resistance to second-line fluoroquinolone drugs and the second-
line injectable drugs. The test also detects XDR-TB. MTBDRsl can be performed on TB bacteria grown by culture from sputum,
which takes a long time (indirect testing), or immediately on sputum (direct testing).
Main results
We examined evidence available up to 30 January 2014 and included 21 studies, 11 of which were in low-income or middle-income
countries.
What do these results mean?
Fluoroquinolone drugs
By indirect testing, the test detected 83% of people with fluoroquinolone resistance and rarely gave a positive result for people without
resistance. In a population of 1000 people, where 170 have fluoroquinolone resistance, MTBDRsl will correctly identify 141 people with
fluoroquinolone resistance and miss 29 people. In this same population of 1000 people, where 830 people do not have fluoroquinolone
resistance, the test will correctly classify 811 people as not having fluoroquinolone resistance and misclassify 19 people as having
resistance (moderate quality evidence).
By direct testing, the test detected 85% of people with fluoroquinolone resistance and rarely gave a positive result for people without
resistance (moderate quality evidence).
Second-line injectable drugs
By indirect testing, the test detected 77% of people with second-line injectable drug resistance and rarely gave a positive result for people
without resistance. In a population of 1000 people, where 230 have second-line injectable drug resistance, MTBDRsl will correctly
identify 177 people with second-line injectable drug resistance and miss 53 people. In this same population of 1000 people, where 770
do not have second-line injectable drug resistance, the test will correctly classify 766 people as not having second-line injectable drug
resistance and misclassify four people as having resistance (moderate quality evidence).
By direct testing, the test detected 94% of people with second-line injectable drug resistance and rarely gave a positive result for people
without resistance (very low quality evidence).
XDR-TB
By indirect testing, the test detected 71% of people with XDR-TB and rarely gave a positive result for people without XDR-TB. In a
population of 1000 people, where 80 have XDR-TB, MTBDRsl will correctly identify 57 people with XDR-TB and miss 23 people. In
this same population of 1000 people, where 920 do not have XDR-TB, the test will correctly classify 909 people as not having XDR-
TB and misclassify 11 people as having XDR-TB (low quality evidence).
There was insufficient evidence to determine the accuracy of MTBDRsl by direct testing for XDR-TB.
Conclusions
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The results show that a positive MTBDRsl result for resistance to the fluoroquinolone drugs or the second-line injectable drugs is
reliable evidence that the person has drug-resistant TB and further conventional drug-resistance testing is not required. However, when
the test reports a negative result, clinicians may still wish to carry out conventional testing.
B A C K G R O U N D
Tuberculosis (TB) is an infectious airborne disease caused by My-
cobacterium tuberculosis bacteria and is the second most common
cause of death from an infectious disease in adults (HIV/AIDS
being first). TB predominantly affects the lungs (pulmonary TB)
but can affect other parts of the body, such as the brain or the
spine. Active TB disease is confirmed by the presence of viable
TB bacilli. The symptoms of pulmonary TB include a persistent
cough (for at least two weeks), fever, night sweats, weight loss,
chills, haemoptysis and fatigue. In 2012, an estimated 8.6 mil-
lion people developed TB and 1.3 million people died from TB
(WHO 2013a). TB that is drug sensitive (also referred to as drug-
susceptible TB) is the most common type of TB and may be ef-
fectively treated with a standardized regimen of first-line anti-TB
drugs (WHO 2013a). However, TB bacilli may become drug re-
sistant, meaning that first-line anti-TB drugs can no longer kill the
bacilli. Drug resistance usually develops because of inappropriate
or incorrect use of first-line drugs but new cases are increasingly
caused by person-to-person transmission (Streicher 2011; Zhao
2012).
The emergence of drug-resistant TB (DR-TB) threatens to desta-
bilise global TB control. In 2012, approximately 4% of new TB
cases were multidrug resistant (WHO 2013a). Therapy for DR-
TB requires treatment for more than 12 months and is toxic and
expensive. In SouthAfrica in 2011, the treatment of approximately
8000 cases of DR-TB, which comprised only 2.2% of the total TB
burden, consumed 32% of the country’s annual national TB bud-
get of US$218 million (Pooran 2013). Fifty percent to 75% of pa-
tients experience unfavourable outcomes, such as death, treatment
failure, or adverse drug reactions (Dheda 2010a; Dheda 2010b).
There are two standardized definitions of DR-TB: multidrug-re-
sistant TB (MDR-TB) and extensively drug-resistant TB (XDR-
TB). MDR-TB is caused by M. tuberculosis which, when tested
microbiologically in the laboratory, is resistant to rifampicin and
isoniazid. These drugs are two of the most effective and widely-
used anti-TBdrugs that formpart of the standardizedfirst-line reg-
imen for drug-susceptible TB. Patients with MDR-TB are com-
monly treated with drugs belonging to the fluoroquinolone (FQ)
and second-line injectable anti-TB drug (SLID) classes. The FQ
drugs include ofloxacin and moxifloxacin and the SLIDs include
amikacin and kanamycin (two aminoglycoside drugs) and capre-
omycin (a cyclic peptide drug). XDR-TB is caused by M. tuber-
culosis resistant to isoniazid, rifampicin, plus any FQ and at least
one of the three SLIDs (amikacin, kanamycin or capreomycin).
Hence, patients with XDR-TB are resistant to both first-line and
second-line drugs.
In South Africa, 80% of MDR-TB is thought to be spread via per-
son-to-person transmission (Streicher 2011) and the same is likely
true ofMDR-TB and XDR-TB inChina (Zhao 2012).Modelling
studies (Basu 2007; Basu 2009; Dowdy 2008) have shown that,
through the expansion of capacity to rapidly diagnose DR-TB,
patient cure rates will be improved through the earlier initiation
of appropriate and effective TB treatment. Importantly, once a
patient is placed on effective treatment, their infectiousness dra-
matically declines within one to two weeks (Menzies 1997). How-
ever, the exact “infectiousness period” for DR-TB remains unclear.
Early treatment initiation may therefore help curtail the spread of
DR-TB through the disruption of person-to-person transmission.
Thus, there is an urgent need for rapid tests that allow the early
detection of drug resistance and the selection of appropriate TB
drugs.
Conventional tests for detecting TB drug resistance, referred to as
drug susceptibility testing (DST), are traditionally ’phenotypic’,
in that bacteria in biological fluid from the patient (usually spu-
tum) is inoculated into a culture medium containing the drug of
interest and the presence (indicating resistance) or absence (indi-
cating susceptibility) of M. tuberculosis growth is detected (Heysell
2012). Such testing is commonly performed indirectly, in that
the pure bacterial culture or isolate grown from the original pa-
tient specimen is re-inoculated into drug-containing media. As the
growth of M. tuberculosis typically takes between two to six weeks
for the initial culture, there is often a significant time delay (two
to six months) associated with the diagnosis of DR-TB, especially
if re-inoculation is required. These delays are often further exacer-
bated by the technical and infrastructure requirements of testing, a
lack of standardised methodologies for certain drugs (which cause
unclear results that require repeating) (Richter 2009), as well as
patient-associated difficulties, such as loss to follow-up. Recently,
new tests for drug resistance such as the Genotype®MTBDRsl test
(henceforth called MTBDRsl) that are rapid (potentially offering
a turn-around time of one to two days) and ’genotypic’ (as they
detect the presence of specific mutations known to be associated
with drug resistance) have offered considerable promise for the
diagnosis of DR-TB.
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One of the challenges in this Cochrane Review is the choice of the
reference standard used to determine the presence or absence of
the target conditions (described below). Phenotypic culture-based
DST is the most widely used reference standard for drug resis-
tance and is recommended by theWHO (WHO2007). However,
phenotypic culture-based DST is acknowledged to be imperfect
and the results are dependent on the concentration of drug used.
Genetic sequencing is widely considered to be the best reference
standard for testing for the presence of drug resistance; but due to
the technical aspects, costs and time associated with this method,
it is rarely feasible to perform it on all samples suspected of DR-TB
or in all regions of the TB genome that might be associated with
resistance. Furthermore, not all genetic determinants or mecha-
nisms of resistance may be known for a particular drug.We discuss
the strengths and limitations of the different reference standards
further below.
Target condition being diagnosed
We considered the following three target conditions: resistance of
M. tuberculosis to FQs; resistance of M. tuberculosis to SLIDs; and
XDR-TB.
Index test(s)
The GenoType® MTBDRsl assay (MTBDRsl, Hain Life Sci-
ences) detects mutations in the gyrA gene (encoding the A-sub-
unit of DNA gyrase), the rrs gene (encoding the 16S rRNA com-
plex) and the embB gene (which, together with the genes embA
and embC, codes for arabinosyltransferase) of the TB-causing M.
tuberculosis complex species (which includes M. tuberculosis,M.
africanum,M. bovis subsp. bovis,M. bovis subsp. caprae,M. bovis
subsp. BCG,M. microti,M. canetti andM. pinnipedii) (Hain Life
Sciences 2012a). The presence of mutations in these genes is
associated with resistance to the FQs (including ofloxacin and
levofloxacin), SLIDs (including kanamycin, amikacin and capre-
omycin) and ethambutol, respectively. Since ethambutol is a first-
line TB drug, we did not determine the accuracy of MTBDRsl
assay for ethambutol resistance in this review.
The assay can be performed either on a patient specimen (direct
testing) or on a culture grown from the patient specimen (indirect
testing). The type of testing, direct or indirect, is dependent on
the quantity of TB in the patient specimen. The manufacturer
recommends that the assay is performed directly on the specimen
if the specimen contains bacilli that can be seen using a light
microscope and an acid-fast stain (smear-positive) (Figure 1).
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Figure 1. Clinical pathway diagram showing how molecular drug susceptibility testing (DST), which may
use the MTBDRsl assay, is applied. A patient with suspected TB or suspected drug-resistant TB supplies a
biological specimen (usually sputum), which is examined by smear microscopy and cultured. If acid-fast bacilli
are observed under the microscope (smear-positive), a molecular DST can be performed directly on the
specimen. If acid-fast bacilli are not observed (smear-negative), molecular DST can only be performed with
acceptable accuracy on the culture isolate grown from the specimen. A molecular test for first-line drug
resistance (for example, the MTBDRplus assay) is performed first and, only if resistance to the first-line drugs
is indicated, the specimen is tested further for resistance to the second-line drugs using the MTBDRsl assay.
Where molecular testing is not available, phenotypic testing for drug resistance may be performed on culture-
positive isolates. Although phenotypic testing is being replaced by molecular-based methods in some settings,
it is still usually performed in research studies seeking to measure the accuracy of the molecular test.
Furthermore, some research studies also use gene sequencing as a reference standard or any specimens with
discordant molecular DST-culture results.
The assay procedure is comprised of three sequential steps when
using direct decontaminated patientmaterial (decontaminated us-
ing the standardN-acetyl-cysteine and sodiumhydroxide (NALC/
NaOH) method), culture isolates in liquid media or when pick-
ing colonies from solid media. These steps are: (1) mycobacterial
genomic DNA is extracted from the patient specimen or culture
isolate; (2) regions within the gyrA, rrs and embB genes are se-
lectively amplified using a multiplex polymerase chain reaction
(PCR) assay; and (3) the amplification products are detected on a
nitrocellulose membrane strip by reverse hybridisation and visu-
alised using a streptavidin-conjugated alkaline phosphatase colour
reaction. The observed bands, each corresponding to a specific
probe, can be used to determine the drug susceptibility profile of
the analysed specimen (an example is shown in Figure 2). The
extraction can also be done indirectly on blood cultures, where a
Middlebrook slant is inoculated prior to picking the colonies from
the agar after incubation for a period of time.
6The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 2. Examples of different GenoType® MTBDRsl strip readouts (Hain Life Sciences 2012b).
A template is supplied by the manufacturer to help read the strips
Appendix 1 where the banding patterns are scored by eye, tran-
scribed and manually fed into the Laboratory Information System
(LIS). In high-volume settings, the GenoScan®, an automated
reader, can be incorporated to interpret the banding patterns auto-
matically and give a suggested interpretation (an example output
of the machine is shown in Appendix 2. If the operator agrees with
the interpretation, the results are automatically downloaded into
the LIS, thus eliminating possible transcription errors. It is impor-
tant to note that the automated reader only provides a suggested
result and requires manual confirmation of the result after the op-
erator has visually inspected the banding pattern. Nonetheless, the
test manual provides fairly straightforward instruction with little
room for variation in interpretation, even human interpretation.
The entire assay procedure can be completed in five hours. The
assay can also be performed on DNA from pure isolates taken
from cultured patient specimens. Once a diagnosis of MDR-TB
has been established, the MTBDRsl can also be used to confirm a
diagnosis of XDR-TB.
Figure 2 shows an example of different MTBDRsl results. The as-
say consists of two internal controls (a conjugate control for con-
firmation of the colorimetric reaction used to visualise bands and
an amplification control to ensure that nucleic acid amplification
reaction has occurred) plus a control for each gene locus (gyrA,
rrs, embB). The two internal controls plus the locus control for
the gene of interest should always be positive; otherwise the assay
cannot be evaluated for that particular drug. Of note is that a result
can be indeterminate for one gene but valid for another (on the
basis of only the gene-specific locus control failing). A band for
the detection of the M. tuberculosis complex (the “TUB” band)
is included. Should the wild-type or mutant probes appear whilst
the locus control for a specific gene is less intense than that of
the amplification control band (AC band) and the TUB band is
interpretable, the locus probes should be considered secondary to
that of the other probes for the gene in question and can thus be
considered for interpretation.
An earlier version of the MTBDRsl manual (version 1) stated that
if the locus band was absent but other non-control bands were
present (even together with their accompanying gene locus control
bands) the assay should be considered non-evaluable (Hain Life
Sciences 2012a). However, the most recent version of the manual
(version 2; Hain Life Sciences 2012b) states: “in rare cases the
TUB zone may be negative while an evaluable resistance pattern
is developed. If so, the presence of a strain belonging to the MTB
complex must be suspected and the assay should be repeated”.
Upon inspection, most of these are nontuberculous mycobacteria
and thus if the TUB band is not present, it is suggested to use the
GenoType® CM/AS kit for the identification of other common
mycobacteria, or additional species should the GenoType® CM/
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AS kit fail to produce a positive identification for any of the 17
species covered by theGenoType®CM/AS kit (HainLife Sciences
2012b).
Clinical pathway
Figure 1 illustrates the clinical pathway. Depending on the setting,
DST is either performed on all patients with confirmed TB or
only on patients who are clinically suspected of having DR-TB
(for example, if the patient’s symptoms have failed to improved on
first-line therapy, or if they still have viable bacilli in their sputum
after an extended period of treatment. As mentioned above, the
manufacturer recommends that if the patient specimen (usually
sputum) is smear-positive the assay be performed directly on the
specimen (direct testing). If smear-negative, it is recommended
that the assay be performed on the culture isolate grown from the
patient specimen (indirect testing). DST for resistance to the sec-
ond-line drugs is only performed if resistance to the first-line drugs
is confirmed. Where routine molecular (genotypic) testing is well
established, phenotypic DST is not usually performed. However,
we expected research studies evaluating the accuracy of molecu-
lar DSTs, such as the MTBDRsl assay, to almost always include
phenotypic DST as a reference standard. Furthermore, we also
expected some studies to use genetic sequencing to resolve any
discordant index test-reference standard results.
Prior test(s)
As detailed in Figure 1, patients who received MTBDRsl testing
will first have received (i) smear microscopy, (ii) liquid culture
(if smear-negative), and (iii) phenotypic or genotypic DST for
resistance to first-line drugs.
Role of index test(s)
MTBDRsl would be used as an initial test replacing phenotypic
culture-based DST as the initial test.
Rationale
Second-line TB drugs are used to treat patients with TB that is
resistant to the most effective and widely used first-line drugs. To
ensure that themost appropriate and least toxic drugs are provided
to patients as quickly as possible, it is critical to know whether a
patient has resistance to FQs alone, resistance to SLIDs alone, or
resistance to both FQs and SLIDs (XDR-TB) as this will guide
the selection of drugs. In addition, the presence of XDR-TB has
major prognostic implications for the patient and for infection
control. The conventional method for the diagnosis of drug re-
sistance (phenotypic culture-based testing) is vulnerable to con-
tamination and the culture can lose viability, meaning it cannot
be tested. This method is also slow and can take several months.
The resulting diagnostic delay results in unnecessary morbidity,
mortality and increased transmission, which is a major driver of
new TB cases. There is a need for rapid assays to improve time-to-
diagnosis and new molecular assays, such as the MTBDRsl assay,
present a promising potential solution.
O B J E C T I V E S
• To assess and compare the diagnostic accuracy of
MTBDRsl for the detection of resistance to FQs in patient
specimens (using direct testing) and culture isolates (using
indirect testing) confirmed as TB positive.
• To assess and compare the diagnostic accuracy of
MTBDRsl for the detection of resistance to SLIDs in patient
specimens (using direct testing) and culture isolates (using
indirect testing) confirmed as TB positive.
• To assess and compare the diagnostic accuracy of
MTBDRsl for the detection of XDR-TB in patient specimens
(using direct testing) and culture isolates (using indirect testing)
confirmed as TB positive.
Secondary objectives
We planned to investigate heterogeneity in relation to the refer-
ence standard (culture-based DST compared with (1) genetic se-
quencing, (2) culture-based DST and genetic sequencing, and (3)
culture-based DST followed by genetic sequencing with discor-
dant results) and individual drugs within a drug class (for exam-
ple, ofloxacin and moxifloxacin within the FQ class). We also pre-
specified in the protocol investigations of heterogeneity in relation
to HIV status, condition of the specimens (fresh or frozen, vol-
ume of specimen), patient population (patients suspected of hav-
ing MDR-TB or XDR-TB) and whether WHO-recommended
critical drug concentrations were used for culture-based reference
testing.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all studies that determined the diagnostic accuracy
of the index test in comparison with a defined reference standard,
including case-control designs, in which cases and controls were
sampled from the same patient population.Weonly included stud-
ies fromwhich data could be extracted for true positives (TP), true
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negatives (TN), false positives (FP) and false negatives (FN). We
excluded unpublished studies reported only in abstracts.
Participants
We included patients and specimens from patients of any age who
were thought to have resistance to any of the second-line TBdrugs,
aswell as patients andpatient specimenswith confirmedMDR-TB
from all settings, irrespective of background burden and patient
population.
Index tests
We included studies that evaluated the MTBDRsl assay.
Target conditions
We considered three target conditions:
1. Resistance to any of the FQs. The FQs include ofloxacin,
levofloxacin and moxifloxacin. We excluded ciprofloxacin
because this drug is infrequently used in DST.
2. Resistance to any of the SLIDs. The SLIDs include two
aminoglycosides, kanamycin and amikacin, and one cyclic
peptide, capreomycin.
3. XDR-TB.
For the FQs, the presence of mutations in each of the genes probed
by the MTBDRsl assay has very high concordance with resistance
to all drugs within that drug class. For example, a mutation in
the gyrA usually means a strain is resistant to each of the FQs:
ofloxacin, levofloxacin and moxifloxacin (Sirgel 2012a). The same
holds true for the rrs gene and the two aminoglycosides, kanamycin
and amikacin (Sirgel 2012b). Evidence is mixed regarding the level
of concordance between resistance to the two aminoglycosides and
capreomycin arising from mutations in the rrs gene. We acknowl-
edge that determining resistance to all three SLIDs together, and
thus including capreomycin with the aminoglycosides, may be
a limitation. However, the index test results are reported in this
manner. We discuss this issue further in the Discussion.
Reference standards
The following reference standards were used to define the target
conditions:
1. Phenotypic culture-based DST: solid culture or a
commercial liquid culture system (BACTEC 460, MGIT 960
and MGIT Manual System, Becton Dickinson, USA)
incorporating the drug of interest.
2. Genetic sequencing of the gyrA or rrs genes, or both.
3. Two reference standards used together: phenotypic culture-
based DST and genetic sequencing of the same samples. If a
specimen was resistant according to phenotypic culture-based
DST or had a mutation in the gyrA or rrs genes, the specimen
was classified as having the target condition. If both phenotypic
culture-based DST and genetic sequencing indicated
susceptibility, the specimen was classified as not having the target
condition.
4. Two reference standards used sequentially: phenotypic
culture-based DST followed by selective testing by genetic
sequencing of samples with discordant results (also referred to as
discrepant analysis). Discordant results may be either index test
positive/phenotypic culture-based DST negative or index test
negative/phenotypic culture-based DST positive.
There are strengths and limitations to each of the reference stan-
dards. As mentioned, phenotypic culture-based DST is the con-
ventional reference standard, but it is considered to be imperfect
and is dependent on the drug concentration threshold used to de-
fine resistance. Genetic sequencing is considered to be more ac-
curate than phenotypic culture-based DST; however, this is only
if it targets all known resistance determining regions, which are
not completely defined for the FQs and the SLIDs. Therefore,
genetic sequencing can miss mutations that may cause drug resis-
tance which fall outside of the targeted genes. Furthermore, ge-
netic sequencing is usually applied only to culture isolates when
results for the index test and the culture-based reference test do
not agree. In this latter situation, there is potential for verification
bias because the same reference standard is not being used to verify
all index test results.
We carried out separate analyses for the different reference stan-
dards, described below. In our primary analysis we used culture-
based DST as the reference standard. We expected all or nearly all
included studies to report results using this reference standard.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
and publication status (published, unpublished, in press and on-
going). We searched for unpublished data as a means of ensuring
the sensitivity of the search for published literature. Unpublished
data in this field may provide misleading results as the data set
is incomplete. While unpublished sources were searched, we did
not include unpublished data in the review. We did not apply date
restrictions to the searches.
Electronic searches
Vittoria Lutje (VL), the Information Specialist for the Cochrane
Infectious Diseases Group, performed literature searching up to
30 January 2014. To identify all relevant studies, she searched the
following databases using the search terms and strategy described
in Appendix 3: Cochrane Infectious Diseases Group Specialized
Register; MEDLINE (Pubmed, 1966 to January 2014); EMBASE
OVID (1980 to January 2014); ISI Web of Knowledge (Science
Citation Index - Expanded (1900 to present), Conference Pro-
ceedings Citation Index- Science (CPCI-S) (1990 to present) and
BIOSIS Previews (1926 to January 2014)); MEDION (http://
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www.mediondatabase.nl/); LILACS (http://lilacs.bvsalud.org/en/
; 1982 to January 2014); and SCOPUS (1995 to January 2014).
VL also searched the metaRegister of Controlled Trials (mRCT;
http://www.controlled-trials.com/) and the search portal of the
World Health Organization (WHO) International Clinical Trials
Registry Platform (www.who.int/trialsearch), to identify ongoing
trials, and ProQuest Dissertations & Theses A&I to identify rele-
vant dissertations.
Searching other resources
We reviewed reference lists of included articles and any relevant re-
view articles identified through the above methods. We contacted
the assay manufacturer (Hain Life Sciences) to identify unpub-
lished studies. We contacted researchers at the Foundation for In-
novative New Diagnostics (FIND), members of the StopTB Part-
nership’s New Diagnostics Working Group and other experts in
the field of TB diagnostics for information on ongoing or unpub-
lished studies.
Data collection and analysis
Selection of studies
Two review authors (GT and JP) independently scrutinized titles
and abstracts identified by electronic literature searching to iden-
tify potentially eligible studies. We selected all citations identified
as suitable during this screen for full-text review. The same two
review authors then independently reviewed full-text papers for
study eligibility using the predefined inclusion and exclusion cri-
teria. For full text articles, we resolved any discrepancies by dis-
cussion with a third review author (KRS). We maintained a list of
excluded studies and their reasons for exclusion.
Data extraction and management
Two review authors (GT and JP) independently extracted a set
of data from each study using a piloted data extraction form. We
resolved any discrepancies by discussion. Based on the pilot, we fi-
nalized the data extraction form.We then independently extracted
data on the following characteristics:
• Details of study: first author; publication year; country
where testing was performed; setting (primary care laboratory,
hospital laboratory, reference laboratory); study design; manner
of participant selection; number of participants enrolled; number
of participants for whom results available; industry sponsorship.
• Characteristics of participants: age (mean, SD; median,
interquartile range; age range); HIV status; smear status; history
of TB; known MDR-TB, pre-XDR-TB or XDR-TB status.
• Target conditions: resistance to FQs; resistance to SLIDs;
XDR-TB.
• Reference standards: name and manufacturer; type;
percentage of patients whose reference standard was
’uninterpretable’ (for example, contaminated, sequencing failed).
• Details of specimen: type (such as expectorated sputum,
induced sputum or culture isolate); condition (fresh or frozen);
definition of a positive smear; type of testing (direct testing or
indirect testing).
• Details of outcomes: the number of TP, TN, FP and FN
results; number of indeterminate assay results.
• Time to treatment initiation: defined as the time from
specimen collection until patient starts treatment.
• Time to diagnosis: defined as the time from specimen
collection until there is an available TB result in lab or clinic, if
the assay was performed in a clinic.
We assigned country income status (high-income or low- andmid-
dle-income) as classified by the World Bank List of Economies
(World Bank 2014). We contacted authors of primary studies for
missing data or clarifications. We entered all data into a database
manager (Microsoft Excel 2012).
For one study that tested the same panel of TB isolates in multiple
centres, we selected one centre that provided results in the middle
range (neither the best nor the worst results).
Whenever possible, we extracted data that used a single patient as
the unit of analysis (one MTBDRsl result per one specimen from
one patient).
When culture-based DST was performed using more than one
drug from the FQs (ofloxacin, moxifloxacin or levofloxacin) or
SLIDs (amikacin, kanamycin or capreomycin), we extracted data
(TP, TN, FP, FN) for each drug and for each class overall. We also
extracted data for the SLIDs as a class overall if culture-based DST
was performed using only one drug.
No studies reported on the number of ’no TB’ or ’no result’ results
obtained fromMTBDRsl, therefore we only reported the propor-
tion of ’indeterminate’ results.
In the 2 x 2 tables of TP, FP, FN and TN, we based the results
of the index test on categorical assay results defined by the visual
readout of the MTBDRsl strip.
Possible results for the Genotype® MTBDRsl assay (as
defined by the product manual)
1. Sensitive to either FQs or SLIDs (referred to as
’aminoglycosides/cyclic peptides’), or both (conjugation and
amplification bands present; TUB band present; gene locus band
present; all wild type (wt) bands for each gene present; no
mutation bands present). In the case of susceptibility to both
drug classes, the test would indicate susceptibility for each, rather
than having a single composite readout specifying XDR-TB.
2. Resistant to either FQs or SLIDs, or both (conjugation and
amplification bands present; TUB band present; gene locus band
present; all, none or some wt bands for each gene present; all,
none or some mutation bands present with similar intensity to
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amplification control). In the case of resistance to both drug
classes, the test would indicate resistance for each, rather than
having a composite readout.
3. Indeterminate (faint bands) or no result (no conjugation or
amplification bands present, no locus band present for the gene
of interest).
4. No TB (negative for MTB complex irrespective of locus
control band).
5. No result (failure of any one of the control bands, as well as
the TUB band).
Assignment of results to the fluoroquinolones, second-line
injectable drugs or both categories
MTBDRsl detects the presence of mutations in genes that cause
drug resistance for drug classes (ie FQs, SLIDs or both), not to
individual drugs within these classes (ofloxacin, moxifloxacin and
levofloxacin in the case of the FQs; amikacin, kanamycin and
capreomycin in the case of SLIDs). Thus, one study might use
phenotypic DST for detection of kanamycin resistance and an-
other study might use phenotypic DST for detection of amikacin
resistance as reference standards to confirm SLID resistance. In
such a scenario, if the phenotypic DST was positive for resistance
and the MTBDRsl result was concordant, we classified the index
case result as true-positive. We adopted the same approach for the
FQs. Similarly, if the index tests reported resistance to a SLID
and, in the case of genetic sequencing being used as a reference
standard, the presence of mutations known to be associated with
drug resistance to the SLIDs was confirmed, we recorded this as
a concordant result positive for resistance to SLIDs. A similar ap-
proach was used for the FQs that used genetic sequencing as a
reference standard.
Assessment of methodological quality
We appraised the quality of the included studies with the Qual-
ity Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool
(Whiting 2011; Appendix 4). QUADAS-2 consists of four do-
mains: patient selection, index test, reference standard, and flow
and timing. We assessed all domains for the potential for risk of
bias and the first three domains for concerns regarding applica-
bility. We used signalling questions in each domain to form judg-
ments about the risk of bias. One review author (GT) piloted the
tool with two included studies and finalized the tool based on ex-
perience gained from the pilot testing. Two review authors then
independently assessed methodological quality of included studies
with the finalized tool.
Statistical analysis and data synthesis
We performed descriptive analysis for key variables (such as coun-
try income status and number of study participants) of the primary
studies using Stata version 12.0 and displayed key study charac-
teristics in Characteristics of included studies.
We used the reference standard ’culture’ in our primary analyses.
We stratified these analyses first by target condition (FQ resistance,
SLID resistance or XDR-TB) and second by type of MTBDRsl
testing (indirect testing or direct testing).Within each stratum (for
example, FQ resistance by indirect testing), we plotted estimates
of the studies’ observed sensitivities and specificities in forest plots
with 95%confidence intervals (CI) and in receiver-operating char-
acteristic (ROC) space using Review Manager (RevMan). Where
adequate data were available, we combined data using meta-anal-
ysis. We performed the majority of meta-analyses by fitting the
bivariate random-effects model (Macaskill 2010; Reitsma 2005)
using Stata version 11 with themetandi and xtmelogit commands.
We compared models with separate and identical variance terms
using likelihood ratio tests to determine the best fitting model. In
situations in which there were fewer than four studies, we deter-
mined summary estimates of sensitivity and specificity by simpli-
fying the bivariate model to two univariate random-effects logis-
tic regression models. When it was not possible to fit the model
and we observed little heterogeneity, we determined summary es-
timates of sensitivity and specificity separately using a fixed-effect
model (Zamora 2006). We presented meta-analysis summaries in
tables and ROC space.
We compared results from studies of direct testing with results
from studies of indirect testing by adding a covariate for the type of
testing to the model. We assessed the significance of the difference
in test accuracy between studies using direct testing and studies
using indirect testing by a likelihood ratio test comparing models
with and without covariate terms. For these comparative analyses,
we first included all studies with relevant data and then included
only those studies that made direct comparisons between direct
and indirect testing with the same participants, where such studies
existed. We present the results according to the stated objectives,
under the appropriate subheadings in the Results section for each
condition: Estimates of the diagnostic accuracy of MTBDRsl us-
ing phenotypic culture-based DST as a reference standard, and
Investigations of heterogeneity for each testing method.
Approach to uninterpretable (indeterminate) MTBDRsl
results
We excluded indeterminate test results from the analyses for de-
termination of sensitivity and specificity. We determined the pro-
portion of indeterminate MTBDRsl results among the primary
studies for each target condition and provided results separately
for indirect and direct testing.
Investigations of heterogeneity
Within each stratum (for example SLID resistance), we investi-
gated heterogeneity through visual examination of forest plots of
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sensitivity and specificity. Then, if sufficient studies were avail-
able, we explored the possible influence of the following pre-spec-
ified categorical covariates: reference standard (culture, genetic se-
quencing, culture and genetic sequencing, culture followed by ge-
netic sequencing) and individual drug (amikacin, kanamycin and
capreomycin). We determined variation in sensitivity and speci-
ficity by adding covariate terms to the meta-analysis models de-
scribed above. The significance of the difference in test accuracy
(for example, between studies using culture versus those using ge-
netic sequencing as the reference standard) was assessed by a like-
lihood ratio test comparing models with and without covariate
terms.
We had also planned to investigate the effect of HIV status, the
condition of the specimen (fresh or frozen), sample volume, the
drug concentration used for culture-based DST (WHO-recom-
mended or not) and patient population (patients thought to have
MDR-TB or XDR-TB) on summary estimates of sensitivity and
specificity in a meta-regression analysis by adding covariate terms
to the bivariate model. However, there were insufficient data for
these additional analyses.
Sensitivity analyses
For our primary analysis using the culture-based DST reference
standard, we performed sensitivity analyses for four QUADAS-2
signalling questions to explore whether the results we found were
robust with respect to the methodological quality of the studies.
We used the following questions:
• Was a consecutive or random sample of patients/specimens
enrolled?
• Was a case-control design avoided?
• Were the reference standard results interpreted without
knowledge of the results of the index test?
• Were the index test results interpreted without knowledge
of the results of the reference standard?
We did not exclude any studies based on these answers.
Assessment of reporting bias
We did not undertake a formal assessment of publication bias
of data included in this review using methods such as fun-
nel plots or regression tests because such techniques have not
been found to be helpful for determining publication bias
within diagnostic test accuracy studies (Macaskill 2010; Tatsioni
2005).
Other analyses
We had intended to summarize two patient outcomes, time-to-
diagnosis and time-to-treatment initiation; however time-to-diag-
nosis was the only one described in the included studies.
R E S U L T S
Results of the search
Our search identified 630 titles (Table 1; Table 2; Figure 3). We
did not add any additional titles after reference review or contact
with experts. After we removed duplicates, 262 titles remained of
which we excluded 140 titles based on a review of title, or abstract,
or both.We retrieved full text articles for 41 citations, of which we
excluded 20, leaving 21 unique studies included in the review and
meta-analysis (Figure 3). We have listed the reasons for exclusion
of studies in the Characteristics of excluded studies section. One
of the 21 studies (Ignatyeva 2012) evaluated a panel of isolates at
four different sites in Eastern Europe and we extracted data for the
one site that neither performed the best or the worst.
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Figure 3. Study flow diagram.
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Methodological quality of included studies
Figure 4 and Figure 5 show the quality assessment of the 21 in-
cluded studies. In the patient selection domain, we considered
10 studies (48%) to be at low risk of bias because participants
were enrolled consecutively or randomly and the study design
was cross-sectional. We considered nine studies to be at high risk
of bias because (1) there was a case-control design (five stud-
ies: Brossier 2010; Hillemann 2009; Ignatyeva 2012; Kiet 2010;
Miotto 2012); (2) enrolment was by convenience (three studies:
Barnard 2012; Lacoma 2012; Lopez-Roa 2012); or (3) the study
had both a case-control design and convenience sampling (one
study: van Ingen 2010). We considered two studies to have un-
clear risk of bias because it was unclear how patients were selected
(Chikamatsu 2012; Fan 2011). With regard to applicability (pa-
tient characteristics and setting), we judged 15 studies (71%) to
include the appropriate patients and settings to address the review
question and six studies to have a high concern about applicabil-
ity (Brossier 2010; Hillemann 2009; Ignatyeva 2012; Kiet 2010;
Miotto 2012; van Ingen 2010). In the index test domain, we con-
sidered two studies at high risk of bias as the index test results
were not interpreted without knowledge of the results of the ref-
erence standard (Chikamatsu 2012; Kiet 2010) and seven stud-
ies at unknown risk of bias because information about blinding
was unavailable (Brossier 2010; Fan 2011; Ferro 2013; Hillemann
2009; Lopez-Roa 2012; Surcouf 2011; Tukvadze 2014). In all but
two studies (Brossier 2010; Tukvadze 2014), the use, conduct and
interpretation of the index test was considered applicable. In the
reference standard domain, we judged eleven studies (52%) to be
at low risk of bias because the reference standard was appropriate
and the results were interpreted without knowledge of the results
of the MTBDRsl assay (Ajbani 2012; Barnard 2012; Chikamatsu
2012; Hillemann 2009; Huang 2011; Ignatyeva 2012;Jin 2013;
Lopez-Roa 2012 Miotto 2012; Tukvadze 2014; Zivanovic 2012.
We judged applicability to be of low concern for all studies in the
reference standard domain. In the flow and timing domain, we
considered 16 studies (76%) to be of low concern for risk of bias
because all patients were accounted for in the analysis, informa-
tion about uninterpretable results was provided and all patients
had the same reference tests performed.We considered five studies
to have unclear risk of bias in the flow and timing domain because
discrepant analysis was performed (Ajbani 2012; Barnard 2012;
Kiet 2010; Lacoma 2012; Lopez-Roa 2012) meaning that not all
patients received culture-based and sequencing reference testing.
Also, we considered one study (Ferro 2013) to have unclear risk
of bias because not all patients were accounted for in the analyses.
We noted industry involvement in seven (33%) studies and this
included: i) donation of MTBDRsl tests (four studies: Hillemann
2009; Miotto 2012; Surcouf 2011; Ferro 2013); ii) preferred pric-
ing of MTBDRsl tests (one study: Barnard 2012); iii) financial
support for non-test related study costs (one study: Said 2012);
and iv) involvement in the design, analysis or manuscript produc-
tion (one study: Ajbani 2012).
Figure 4. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Findings
Of the 21 included studies, eight reported on MTBDRsl testing
for resistance to FQs, SLIDs and XDR-TB, 12 reported on testing
for resistance to FQs and SLIDs, and one reported on testing for
resistance to FQs only. Fourteen studies reported on MTBDRsl
performance when done directly on patient specimens, five stud-
ies reported on MTBDRsl when performed indirectly on isolates
grown from the specimens and a further two studies contained
information on both testing methods. Of the 21 studies, 11 used
only phenotypic culture-based DST, seven used sequencing and
culture on all specimens, three used culture followed by the se-
quencing of discrepant results and one used sequencing alone.
The median (interquartile range (IQR)) number of participants
in each study was 100 (50.75, 229.5). The proportion of patients
screened with resistance to a FQ, SLID, or XDR-TB (according to
phenotypic culture-based testing) were 30% (95% CI 28 to 32),
32% (95% CI 30 to 34), or 15% (95% CI 13 to 17), respectively.
We presented key characteristics for the 21 studies in the
Characteristics of included studies section. The majority (15 stud-
ies, 71%) were of cross-sectional study design. One study (Barnard
2012) included extrapulmonary specimens that we excluded from
the analysis. Eleven studies (58%) were located in low-income or
middle-income countries. All studies but two (Fan 2011, written
in Chinese, and Chikamatsu 2012, written in Japanese) were in
English.
I. Fluoroquinolone resistance detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
phenotypic culture-based DST as a reference standard
1. Indirect testing
We present forest plots of MTBDRsl sensitivity and specificity
when performed indirectly for the detection of FQ resistance for
16 studies (1766 participants) that used phenotypic culture-based
DST as a reference standard in Figure 6. For individual studies,
sensitivity estimates ranged from 57% to 100% and specificity
estimates ranged from 77% to 100%. In the meta-analysis, the
pooled sensitivity and specificity were 83.1% (95% CI 78.7 to
86.7) and 97.7% (95% CI 94.3 to 99.1), respectively.
16The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 6. Forest plots of MTBDRsl sensitivity and specificity when performed indirectly or directly for FQ
resistance detection and using phenotypic culture-based DST as a reference standard. The individual studies
are ordered by decreasing sensitivity. TP = true positive; FP = false positive; FN = false negative; TN = true
negative. Values between brackets are the 95% CIs of sensitivity and specificity. The figure shows the
estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
2. Direct testing
In Figure 6 we show forest plots of MTBDRsl sensitivity and
specificity when performed directly for the detection of resistance
to FQs for seven studies (1033 participants) that used phenotypic
culture-based DST as a reference standard. For individual studies,
sensitivity estimates ranged from 50% to 100% and specificity
estimates ranged from 91% to 100%. In the meta-analysis, the
pooled sensitivity and specificity were 85.1% (95% CI 71.9 to
92.7) and 98.2% (95% CI 96.8 to 99.0), respectively.
3. Comparison of indirect versus direct testing
(i) Diagnostic accuracy
We present results comparing indirect and direct MTBDRsl test-
ing for detection of FQ resistance in Table 3, Table 4 and Figure
7. There was no evidence of a statistically significant difference in
MTBDRsl accuracy between indirect and direct testing and using
culture-based DST as a reference standard when the test was per-
formed in different populations (indirect comparison, P = 0.549).
Direct comparisons within the same population were not possible
because no studies performed direct and indirect MTBDRsl test-
ing on specimens or isolates from the same patients.
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Figure 7. Summary plots of MTBDRsl sensitivity and specificity comparing detection of fluoroquinolone
resistance by indirect and direct testing. The solid circles correspond to the summary estimates of sensitivity
and specificity and are shown with 95% confidence regions (dotted lines) and 95% prediction regions (dashed
lines).
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(ii) Indeterminate rates
For indirect testing for FQ resistance, four (0.2%) of 1766
MTBDRsl results were indeterminate (three culture DST resis-
tant and one culture DST sensitive), whereas for direct testing
20 (1.9%) of 1033 were MTBDRsl indeterminate (P < 0.001; 14
were culture DST-sensitive and six did not report a culture-based
DST result).
B. Investigations of heterogeneity
1. Indirect testing
(i) Type of reference standard
We present MTBDRsl accuracy estimates for detection of FQ
resistance against different reference standards in Table 3 and
Appendix 5.
Reference standard is genetic sequencing:
For individual studies (seven in total), sensitivity estimates ranged
from 85% to 100% and specificity estimates ranged from 92% to
100%. In the meta-analysis, the pooled sensitivity and specificity
were 99.3% (95% CI 85.9 to 100.0) and 99.7% (95% CI 92.0
to 100.0), respectively. The accuracy using this reference standard
was higher than when culture-based DST was used (P < 0.001
for indirect statistical comparisons, Table 3; P < 0.001 for direct
statistical comparisons, Table 4). Five studies sequenced the gyrA
gene and two sequenced gyrA and gyrB.
Reference standard is culture-based DST and genetic sequencing
(ie both investigations performed in all isolates):
For individual studies (seven in total), sensitivity estimates ranged
from 74% to 91% and specificity estimates ranged from 99% to
100%. In the meta-analysis, the pooled sensitivity and specificity
were 82.0% (95% CI 77.7 to 85.6) and 99.8% (95% CI 98.5
to 100.0), respectively. The accuracy using this reference standard
was higher than when culture-based DST was used (P < 0.001 for
indirect comparisons, Table 3; P < 0.001 for direct comparisons,
Table 4).
Reference standard is culture-based DST followed by genetic se-
quencing of discrepant index test-culture-based DST results:
For individual studies (three in total), sensitivity estimates ranged
from 73% to 100% and specificity estimates ranged from 94% to
100%. In the meta-analysis, the pooled sensitivity and specificity
were 83.7% (95% CI 74.2 to 90.8) and 99.7% (95% CI 98.4
to 100.0), respectively. Comparisons between accuracy estimates
using this reference standard and culture-based DST were not
possible given the small number of studies in the former group.
(ii) Drugs used in the culture-based DST
We present MTBDRsl accuracy estimates for detection of resis-
tance to ofloxacin and moxifloxacin against a phenotypic culture-
based reference standard in Table 3, Table 4 and Appendix 6.
For ofloxacin resistance, sensitivity estimates ranged from 70% to
100% and specificity estimates ranged from 91% to 100%. In the
meta-analysis, the pooled sensitivity and specificity were 82.9%
(95% CI 79.5 to 87.1) and 98.2% (95% CI 96.1 to 99.1), re-
spectively. For moxifloxacin resistance, sensitivity estimates ranged
from 57% to 100% and specificity estimates from 77% to 100%.
In the meta-analysis, the pooled sensitivity and specificity were
91.4% (95% CI 64.7 to 98.4) and 90.6% (95% CI 79.3 to 96.1),
respectively. The accuracy of MTBDRsl when performed indi-
rectly was not different for ofloxacin versus moxifloxacin (indirect
comparison, P = 0.091). Appendix 7 presents a summary ROC
plot of sensitivity versus specificity comparing test performance
for detection of resistance to the individual FQ drugs.
(iii) Drug concentration used in culture-based DST
Nine studies used theWHO-recommended critical concentration
of ofloxacin, whereas two did not (Jin 2013; Kiet 2010). Ferro
2013 used theWHO-recommended critical concentration for low
level moxifloxacin resistance whereas Lacoma 2012 used the con-
centration recommended for high level resistance. Two studies
(Fan 2011; van Ingen 2010) did not used the recommended crit-
ical concentration of moxifloxacin. Comparisons between accu-
racy estimates for each drug according to concentration were not
possible given the small number of studies.
2. Direct testing
(i) Type of reference standard
Reference standard is genetic sequencing:
No studies performed direct MTBDRsl testing and used genetic
sequencing as a reference standard.
Reference standard is culture-based DST and genetic sequencing
(ie both investigations performed in all isolates):
No studies performed directMTBDRsl testing and used both phe-
notypic culture-based DST and genetic sequencing (performed in
all isolates) as a reference standard.
Reference standard is culture-based DST followed by genetic se-
quencing of discrepant index test-culture-based DST results:
Two studies reported MTBDRsl sensitivity and specificity when
performed directly for the detection of resistance to FQs, with
19The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
phenotypic culture-basedDST and genetic testing performed only
on discrepant results as a reference standard. The reported sen-
sitivities were 91% and 96% and the reported specificities were
98% and 99%.
(ii) Drugs used in the culture-based DST
Sensitivity estimates for MTBDRsl for ofloxacin resistance by di-
rect testing against a phenotypic culture-based reference standard
for three studies ranged from 89% to 100%. Specificity estimates
from 98% to 100%. No studies performed MTBDRsl by direct
testing for moxifloxacin resistance.
(iii) Drug concentration used in culture-based DST
All three studies in this category used the WHO-recommended
critical concentration for ofloxacin.
II. SLID resistance detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
phenotypic culture-based DST as a reference standard
1. Indirect testing
We present forest plots of MTBDRsl sensitivity and specificity
when performed indirectly for the detection of resistance to SLIDs
for 14 studies (1637 participants) that used phenotypic culture-
based DST as a reference standard in Figure 8. For individual stud-
ies, sensitivity estimates ranged from 25% to 100% and specificity
estimates ranged from 86% to 100%. In the meta-analysis, the
pooled sensitivity and specificity were 76.9% (95% CI 61.1 to
87.6) and 99.5% (95% CI 97.1 to 99.9), respectively.
Figure 8. Forest plots of MTBDRsl sensitivity and specificity for SLID resistance detection when performed
indirectly or directly and using phenotypic culture-based DST as a reference standard. The individual studies
are ordered by decreasing sensitivity. TP = true positive; FP = false positive; FN = false negative; TN = true
negative. Values between brackets are the 95% CIs of sensitivity and specificity. The figure shows the
estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line)
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2. Direct testing
In Figure 8 we show forest plots ofMTBDRsl sensitivity and speci-
ficity when performed directly for the detection of resistance to
SLIDs for six studies (947 participants) that used phenotypic cul-
ture-based DST as a reference standard. For individual studies,
sensitivity estimates ranged from 9% to 100%, with one study
from Eastern Europe reporting low sensitivity (Kontsevaya 2013).
Specificity estimates ranged from 67% to 100%. In the meta-
analysis, the pooled sensitivity and specificity were 94.4% (95%
CI 25.2 to 99.9) and 98.2% (95% CI 88.9 to 99.7), respectively.
When the study from Eastern Europe that reported low sensitivity
(Kontsevaya 2013) was removed (Appendix 8), the pooled sen-
sitivity increased to 98.0% (95% CI 39.6 to 100.0), while the
pooled specificity decreased to 97.8% (95% CI 86.4 to 99.7).
3. Comparison of indirect versus direct testing
(i) Diagnostic accuracy
We present results comparing indirect and direct MTBDRsl test-
ing for SLID resistance in Table 3, Table 4 and Figure 9. The
pooled sensitivity for direct testing (94.4%, 95% CI 25.2 to 99.9)
was similar to the pooled estimate for indirect testing (76.9%,
95% CI 61.1 to 87.6) when the test was performed in different
populations using all studies (indirect comparisons, P = 0.451).
The pooled specificity was lower (indirect comparisons, P = 0.005)
for direct testing (98.2%, 95% CI 88.9 to 99.7) when compared
to indirect testing (99.5%, 95% CI 97.1 to 99.9) .
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Figure 9. Summary plots of MTBDRsl sensitivity and specificity comparing detection of resistance for
second-line injectable drugs by indirect and direct testing. The solid circles correspond to the summary
estimates of sensitivity and specificity and are shown with 95% confidence regions (dotted lines) and 95%
prediction regions (dashed lines).
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(ii) Indeterminate rates
For indirect testing for SLID resistance, three (0.4%) of 774
MTBDRsl results were indeterminate (one culture DST resistant
and two culture DST sensitive; three studies did not report these),
whereas for direct testing 53 (6.1%) of 873 were MTBDRsl inde-
terminate (four were culture DST resistant, 22 were culture DST
susceptible and 27 did not have a culture-based DST result; one
study did not report indeterminate results) (P < 0.001).
B. Investigations of heterogeneity
1. Indirect testing
(i) Type of reference standard
We present MTBDRsl accuracy estimates for detection of SLID
resistance against different reference standards in Table 3 and
Appendix 9.
Reference standard is genetic sequencing:
For individual studies (six in total), sensitivity estimates ranged
from 62% to 100% and specificity estimates ranged from 96% to
100%. In the meta-analysis, the pooled sensitivity and specificity
were 97.8% (95% CI 77.0 to 99.7) and 99.5% (95% CI 94.5
to 100.0), respectively. The accuracy using this reference standard
was higher than when culture-based DST was used (P = 0.017
for indirect statistical comparisons, Table 3; P = 0.045 for direct
statistical comparisons, Table 4). All six studies sequenced only
the rrs gene.
Reference standard is culture-based DST and genetic sequencing
(ie both investigations performed in all isolates):
For individual studies (seven in total), sensitivity estimates ranged
from 30% to 85% and specificity estimates ranged from 99% to
100%. In the meta-analysis, the pooled sensitivity and specificity
were 56.7% (95% CI 40.8 to 71.3) and 99.9% (95% CI 99.2
to 100.0), respectively. The accuracy using this reference standard
was higher than when culture-based DST was used (P = 0.008 for
indirect comparisons, Table 3).
Reference standard is culture-based DST followed by genetic se-
quencing of discrepant index test-culture-based DST results:
For individual studies (three in total), sensitivity estimates ranged
from 34% to 100% and specificity estimates ranged from 95% to
100%. We did not determine summary estimates because there
were only three studies and the sensitivity was variable.
(ii) Drugs used in the culture-based DST
We present MTBDRsl accuracy estimates for detection of resis-
tance to amikacin, kanamycin and capreomycin by indirect testing
against a phenotypic culture-based reference standard in Table 3
andFigure 10. For amikacin resistance, sensitivity estimates ranged
from 80% to 100% and specificity estimates ranged from 97% to
100%. In the meta-analysis, the pooled sensitivity and specificity
were 87.9% (95% CI 82.1 to 92.0) and 99.5% (95% CI 97.5 to
99.9), respectively. For kanamycin resistance, sensitivity estimates
ranged from 25% to 100% and specificity estimates from 86% to
100%. The pooled sensitivity and specificity were 66.9% (95%CI
44.1 to 83.8) and 98.6% (95%CI 96.1 to 99.5). For capreomycin
resistance, sensitivity estimates ranged from 21% to 100% and
specificity estimates from 86% to 100%. The pooled sensitivity
and specificity were 79.5% (95% CI 58.3 to 91.4) and 95.8%
(95% CI 93.4 to 97.3). Figure 11 presents a summary ROC plot
of sensitivity versus specificity comparing test performance for de-
tection of resistance to the individual SLIDs by indirect testing.
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Figure 10. Forest plots of MTBDRsl sensitivity and specificity when performed indirectly for the detection
of resistance to amikacin (Ak), kanamycin (Kn) and capreomycin (Cm) using culture as a reference standard.
The individual studies are ordered by decreasing sensitivity. TP = true positive; FP = false positive; FN = false
negative; TN = true negative. Values between brackets are the 95% CIs of sensitivity and specificity. The figure
shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
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Figure 11. Summary plots of MTBDRsl sensitivity and specificity comparing indirect detection of resistance
for amikacin (Ak), kanamycin (Kn) and capreomycin (Cm) using culture as a reference standard. The solid
circles correspond to the summary estimates of sensitivity and specificity and are shown with 95% confidence
regions (dotted lines) and 95% prediction regions (dashed lines).
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(iii) Drug concentration used in culture-based DST
Five studies used the WHO-recommended critical concentration
of amikacin, whereas four did not. Two studies (Huang 2011;
Ferro 2013) used the WHO-recommended critical concentra-
tion of kanamycin, whereas seven did not. Seven studies used the
WHO-recommended critical concentration of capreomycin, two
did not (Brossier 2010; Huang 2011) and one (Jin 2013) did not
report the critical concentration used. Comparisons between ac-
curacy estimates according to drug concentration were not possi-
ble given the small number of studies and participants.
2. Direct testing
(i) Type of reference standard
Reference standard is genetic sequencing:
No studies performed direct MTBDRsl testing and used genetic
sequencing as a reference standard.
Reference standard is culture-based DST and genetic sequencing
(ie both investigations performed in all isolates):
No studies performed directMTBDRsl testing and used both phe-
notypic culture-based DST and genetic sequencing (performed in
all isolates) as a reference standard.
Reference standard is culture-based DST followed by genetic se-
quencing of discrepant index test culture-based DST results:
We found two studies, both of which reported perfect sensitivity
and specificity: 100% (95% CI 85 to 100) and 100% (95% CI
97 to 100) for Ajbani 2012 and 100% (95% CI 92 to 100) and
100% (95% CI 98 to 100) for Barnard 2012, respectively.
(ii) Drugs used in the culture-based DST
We present MTBDRsl accuracy estimates for detection of resis-
tance to amikacin, kanamycin and capreomycin by direct testing
against a phenotypic culture-based reference standard in Figure 12.
For amikacin resistance, sensitivity estimates ranged from 64% to
100% and specificity estimates ranged from 89% to 100%. In the
meta-analysis, the pooled sensitivity and specificity were 97.3%
(95% CI 55.1 to 99.9) and 99.3% (95% CI 92.3 to 99.9), respec-
tively. For kanamycin resistance, sensitivity estimates ranged from
9% to 100% and specificity estimates from 91% to 100%. In the
meta-analysis, the pooled sensitivity and specificity were 72.1%
(95% CI 9.5 to 98.5) and 98.8% (95% CI 89.3 to 99.9), re-
spectively. For capreomycin resistance, sensitivity estimates ranged
from 57% to 100% and specificity estimates from 90% to 100%.
The pooled sensitivity and specificity were 68.7% (95% CI 55.4
to 79.5) and 97.0% (95% CI 89.6 to 99.2). Figure 13 presents a
summary ROC plot of sensitivity versus specificity comparing test
performance for detection of resistance to the individual SLIDs
by direct testing.
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Figure 12. Forest plots of MTBDRsl sensitivity and specificity when performed directly for the detection of
resistance to amikacin (Ak), kanamycin (Kn) and capreomycin (Cm) using culture as a reference standard. The
individual studies are ordered by decreasing sensitivity. TP = true positive; FP = false positive; FN = false
negative; TN = true negative. Between brackets are the 95% CI of sensitivity and specificity. The figure shows
the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
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Figure 13. Summary plots of MTBDRsl sensitivity and specificity comparing direct detection of resistance
for amikacin (Ak), kanamycin (Kn) and capreomycin (Cm) using culture as a reference standard. The solid
circles correspond to the summary estimates of sensitivity and specificity and are shown with 95% confidence
regions (dotted lines) and 95% prediction regions (dashed lines).
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(iii) Drug concentration used in culture-based DST
Three studies in this category used the WHO-recommended
critical concentration for amikacin. One study (Barnard 2012)
used a method (culture on Middlebrook 7H11 media) for which
the WHO does not recommend a critical concentration. Two
studies used the WHO-recommended critical concentration for
kanamycin (Ajbani 2012; Tukvadze 2014) and two (Kontsevaya
2013; Miotto 2012) did not. All four studies used the WHO-
recommended critical concentration for capreomycin.
III. XDR-TB detection
A. Estimates of the diagnostic accuracy of MTBDRsl using
phenotypic culture-based DST as a reference standard
1. Indirect testing
In Figure 14 we present forest plots of MTBDRsl sensitivity and
specificity for XDR-TB for eight studies (880 participants) that
used phenotypic culture-based DST as a reference standard. For
individual studies, sensitivity estimates ranged from 20% to 100%
and specificity estimates ranged from 96% to 100%. In the meta-
analysis, the pooled sensitivity and specificity were 70.9% (95%
CI 42.9 to 88.8) and 98.8% (95% CI 96.1 to 99.6), respectively.
Figure 14. Forest plots of MTBDRsl sensitivity and specificity when performed indirectly and directly for the
detection of XDR-TB using phenotypic culture-based DST as a reference standard. The individual studies are
ordered by decreasing sensitivity. TP = true positive; FP = false positive; FN = false negative; TN = true
negative. Between brackets are the 95% CI of sensitivity and specificity. The figure shows the estimated
sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
2. Direct testing
We show forest plots of MTBDRsl sensitivity and specificity for
XDR-TB for three studies (664 participants) that used pheno-
typic culture-based DST as a reference standard in Figure 14. We
observed considerable heterogeneity and did not calculate pooled
estimates. The test yielded sensitivities and specificities of 92%
(95% CI 75 to 99) and 100% (95% CI 99 to 100) for Barnard
2012, 14% (95% CI 5 to 35) and 100% (95% CI 93 to 100) for
Kontsevaya 2013 and 100% (95% CI 16 to 100) and 94% (95%
CI 84 to 99) for Miotto 2012.
3. Comparison of indirect versus direct testing
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(i) Diagnostic accuracy
We present results for indirect MTBDRsl testing for XDR-TB in
Table 5. The pooled sensitivity was 70.9% (95% CI 42.9 to 88.8)
and the pooled specificity was 98.8% (95% CI 96.1 to 99.6). We
were unable to compare these estimates with those for direct test-
ing, because we did not calculate pooled estimates for direct testing
as there were only three studies with considerable heterogeneity.
(ii) Indeterminate rates
For indirect testing for XDR-TB, one (0.1%) of 880 MTBDRsl
results was indeterminate (one culture DST sensitive), whereas for
direct testing 12 (1.8%) of 644 were MTBDRsl indeterminate
(five were culture DST susceptible and seven did not report a
culture-based DST result) (P < 0.001).
B. Investigations of heterogeneity
1. Indirect testing
We present MTBDRsl accuracy estimates for detection of XDR-
TB against different reference standards in Table 5.
(i) Type of reference standard
Reference standard is genetic sequencing:
For individual studies (three in total), sensitivity estimates were
all 100% and specificity estimates ranged from 95% to 100%.
In the meta-analysis, the pooled sensitivity and specificity were
100% (95% CI 94.6 to 100) and 97.5% (95% CI 95.6 to 98.7),
respectively.
Reference standard is culture-based DST and genetic sequencing
(ie both investigations performed in all isolates):
We found two studies. Sensitivity and specificity estimates for Jin
2013 were 56% (95% CI 45 to 67) and 99% (95% CI 96 to 100),
respectively, and 71% (95% CI 44 to 90) and 99% (95% CI 95
to 100), respectively for Miotto 2012. The pooled sensitivity and
specificity were 58.8% (95% CI 49.1 to 67.9) and 98.8% (95%
CI 96.8 to 99.5), respectively.
Reference standard is culture-based DST followed by genetic se-
quencing of discrepant index test-culture-based DST results:
No studies performed indirect MTBDRsl testing when performed
indirectly for XDR-TB and used phenotypic culture-based DST
and genetic sequencing for discordant analysis as a reference stan-
dard.
(ii) Drugs used in the culture-based DST
One (Kiet 2010) of the eight studies that performed indirect test-
ing for XDR-TB and used cultured-based DST as a reference
standard used ofloxacin and kanamycin. Two studies (Hillemann
2009; Zivanovic 2012) used ofloxacin, amikacin and capre-
omycin. One study (Miotto 2012) used ofloxacin, amikacin and
kanamycin. One study (Chikamatsu 2012) used levofloxacin,
amikacin, kanamycin and capreomycin. One study (Ignatyeva
2012) used ofloxacin, amikacin, kanamycin and capreomycin.
One study (Jin 2013) used ofloxacin, kanamycin and capreomycin.
One study (van Ingen 2010) used moxifloxacin, amikacin and
ofloxacin. As all but two studies used a different combination of
drugs, we did not compare test performance according to drugs
used in the culture-based DST.
(iii) Drug concentration used in culture-based DST
Four studies in this category used the WHO-recommended criti-
cal concentration for ofloxacin (Hillemann 2009; Ignatyeva 2012;
Miotto 2012; Zivanovic 2012) and two did not (Jin 2013; Kiet
2010). van Ingen 2010 used moxifloxacin but did not use the
WHO-recommended critical concentration. For the study that
used levofloxacin (Chikamatsu 2012) the WHO does not rec-
ommend a critical concentration for the type of culture used
(Ogawa culture). For the six studies that used amikacin, four
used the WHO-recommended critical concentration (Hillemann
2009; Ignatyeva 2012;Miotto 2012; Zivanovic 2012), one did not
report the concentration used (Chikamatsu 2012) and one used
a type of culture-based testing (Middlebrook 7H10 media) for
which the WHO did not specify a recommended critical concen-
tration (van Ingen 2010). Of the five studies that used kanamycin,
three did not use the WHO-recommended critical concentration
(Jin 2013; Kiet 2010; Miotto 2012), one did not report the con-
centration used (Chikamatsu 2012) and one used a type of culture-
based testing (MGIT 960) for which the WHO did not specify a
recommended critical concentration (Ignatyeva 2012). Of the six
studies that used capreomycin, five used theWHO-recommended
critical concentration (Hillemann 2009; Ignatyeva 2012; Miotto
2012; van Ingen 2010; Zivanovic 2012) and two did not report
the concentration used (Chikamatsu 2012; Jin 2013).
2. Direct testing
(i) Type of reference standard
Reference standard is genetic sequencing:
No studies performed direct MTBDRsl testing for XDR-TB and
used genetic sequencing as a reference standard.
Reference standard is culture-based DST and genetic sequencing
(ie both investigations performed in all isolates):
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No studies performed directMTBDRsl testing and used both phe-
notypic culture-based DST and genetic sequencing (performed in
all isolates) as a reference standard.
Reference standard is culture-based DST followed by genetic se-
quencing of discrepant index test-culture-based DST results:
We found a single study (Miotto 2012) that used phenotypic cul-
ture-based DST and performed genetic testing only on discrepant
results. This study reported a sensitivity of 92% (95% CI 75 to
99) and a specificity of 100% (95% CI 99 to 100).
Sensitivity analyses
We undertook sensitivity analyses by limiting inclusion in the
meta-analyses to: studies with consecutive or random selection of
samples, studies with cross-sectional design, studies where index
test results were blinded to reference standard results, and studies
where reference standard results were blinded to index test results.
Table 6 contains sensitivity analyses for the FQs. For the SLIDs
(Table 7), using culture-based DST as the reference standard and
direct testing, the pooled sensitivity estimate was lower when we
dropped studies that enrolled patients by convenience. However,
in all the analyses for the detection SLID resistance by direct test-
ing, we found wide 95% CIs suggesting less precision around the
pooled estimates. The other sensitivity analyses made no differ-
ence to any of the findings.
Other analyses
Only four studies described the effect of MTBDRsl on time-to-di-
agnosis. Lopez-Roa 2012 reported it to have a time-to-diagnosis of
eight hours, compared to DST using the agar proportion method
(21 days) or theMGIT 960 method (eight days). Said 2012 stated
that MTBDRsl had a median time-to-diagnosis of two days, com-
pared to 11 days for the agar proportion method. Tukvadze 2014
noted a median time-to-diagnosis using MTBDRsl of 10 days,
versus 70 to 104 days for culture-based DST. Barnard 2012 re-
ported it to have a median turn-around-time of one day (after
the diagnosis of first-line resistance), whereas the median turn-
around-time for phenotypic culture-based DST was 31 days.
31The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Summary of findings
Patients Patients or specimens of any age presumed to have resistance to any of the second-line TB drugs and those
with confirmed MDR-TB
Prior testing Patients who received MTBDRsl testing will first have received smear microscopy or culture (if smear-negative)
or both for the detection of TB and phenotypic or genotypic DST for resistance to first-line TB drugs
Settings Intermediate or central level laboratories
Index (new) test MTBDRsl assay
Reference standard Culture-based DST
Studies Cross-sectional and case control studies in which cases and controls were sampled from the same patient
population
A. MTBDRsl for fluoroquinolones by indirect testing
Prevalence Sensitivity (95% CI)
83.1% (78.7 to 86.7)
Specificity (95% CI)
97.7% (94.3 to 99.1)
Number of participants
(studies)
Quality of the evidence
(GRADE)*
12% A diagnostic test does not
always accurately detect
all of the people who ac-
tually have the disease or
condition in question
120 people (out of 1000
people) have (as yet unde-
tected) resistance. Of the
1000 people who take the
MTBDRsl test, 100 people
will be correctly identified
as having resistance (TPs)
. However, 20 people with
resistance will remain un-
detected; their ‘ ‘ negative’’
test results will be incor-
rect (FNs)
A diagnostic test does not
always accurately identify
all of the people who do not
have the disease or condi-
tion in question
880 people (out of 1000
people) do not have resis-
tance. Of the 1000 peo-
ple who take the MTBDRsl
test, 860 of these people
will be correctly identified
as not having resistance
(TNs). However, 20 peo-
ple will be incorrectly iden-
tified; their ‘ ‘ positive’’ test
results will suggest they
have resistance (FPs)
1766 (16 studies) Quality of the evidence in-
dicates how likely it is that
the accuracy of the test
will be substantially differ-




17% 170 people (out of 1000
people) have (as yet unde-
tected) resistance. Of the
1000 people who take the
MTBDRsl test, 141 people
will be correctly identified
as having resistance (TPs)
. However, 29 people with
resistance will remain un-
detected; their ‘ ‘ negative’’
830 people (out of 1000
people) do not have resis-
tance. Of the 1000 peo-
ple who take the MTBDRsl
test, 811 of these people
will be correctly identified
as not having resistance
(TNs). However, 19 peo-
ple will be incorrectly iden-
tified; their ‘ ‘ positive’’ test
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test results will be incor-
rect (FNs)
results will suggest they
have resistance (FPs)
21% 210 people (out of 1000
people) have (as yet unde-
tected) resistance. Of the
1000 people who take the
MTBDRsl test, 175 people
will be correctly identified
as having resistance (TPs)
. However, 35 people with
resistance will remain un-
detected; their ‘ ‘ negative’’
test results will be incor-
rect (FNs)
790 people (out of 1000
people) do not have resis-
tance. Of the 1000 peo-
ple who take the MTBDRsl
test. 772 of these people
will be correctly identified
as not having resistance
(TNs). However, 18 peo-
ple will be incorrectly iden-
tified; their ‘ ‘ positive’’ test
results will suggest they
have resistance (FPs)
B. MTBDRsl for fluoroquinolones by direct testing
Prevalence Sensitivity (95% CI)
85.1% (71.9 to 92.7)
Specificity (95% CI)
98.2% (96.8 to 99.0)
Number of participants
(studies)
Quality of the evidence
(GRADE)*
12% 120 people (out of 1000
people) have (as yet unde-
tected) resistance. Of the
1000 people who take the
MTBDRsl test, 102 people
will be correctly identified
as having resistance (TPs)
. However, 18 people with
resistance will remain un-
detected; their ‘ ‘ negative’’
test results will be incor-
rect (FNs)
880 people (out of 1000
people) do not have resis-
tance. Of the 1000 peo-
ple who take the MTBDRsl
test,864 of these people
will be correctly identified
as not having resistance
(TNs). However, 16 peo-
ple will be incorrectly iden-
tified; their ‘ ‘ positive’’ test
results will suggest they
have resistance (FPs)
1033 (7 studies) Quality of the evidence in-
dicates how likely it is that
the accuracy of the test
will be substantially differ-




17% 170 people (out of 1000
people) have (as yet unde-
tected) resistance. Of the
1000 people who take the
MTBDRsl test, 145 people
will be correctly identified
as having resistance (TPs)
. However, 25 people with
resistance will remain un-
detected; their ‘ ‘ negative’’
test results will be incor-
rect (FNs)
830 people (out of 1000
people) do not have resis-
tance. Of the 1000 peo-
ple who take the MTBDRsl
test, 815 of these people
will be correctly identified
as not having resistance
(TNs). However, 15 peo-
ple will be incorrectly iden-
tified; their ‘ ‘ positive’’ test
results will suggest they
have resistance (FPs)
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21% 210 people (out of 1000
people) have (as yet unde-
tected) resistance. Of the
1000 people who take the
MTBDRsl test, 179 people
will be correctly identified
as having resistance (TPs)
. However, 31 people with
resistance will remain un-
detected; their ‘ ‘ negative’’
test results will be incor-
rect (FNs)
790 people (out of 1000
people) do not have resis-
tance. Of the 1000 peo-
ple who take the MTBDRsl
test. 776 of these people
will be correctly identified
as not having resistance
(TNs). However, 14 peo-
ple will be incorrectly iden-
tified; their ‘ ‘ positive’’ test
results will suggest they
have resistance (FPs)
*We deducted one point for limitations. We did not deduct points for indirectness; however we consider sensitivity and specificity to be
surrogates for patient-important outcomes and high accuracy does not mean that patients will get better.
DST = drug susceptibility testing; TP = true positive; FP = false positive; TN = true negative; FN = false negative.
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Patients Patients or specimens of any age presumed to have resistance to any of the second-line TB drugs and those with confirmed MDR-TB
Prior testing Patients who received MTBDRsl testing will first have received smear microscopy or culture (if smear-negative) or both for the
detection of TB and phenotypic or genotypic DST for resistance to first-line TB drugs
Settings Intermediate or central level laboratories
Index (new) test MTBDRsl assay
Reference standard Culture-based DST
Studies Cross-sectional and case control studies in which cases and controls were sampled from the same patient population

























































































































































































Prevalence Sensitivity (95% CI)
76.9% (61.1 to 87.6)
Specificity (95% CI)
99.5% (97.1 to 99.9)
Number of participants (stud-
ies)
Quality of the evidence
(GRADE)*
15% A diagnostic test does not al-
ways accurately detect all of the
people who actually have the
disease or condition in question
150 people (out of 1000 peo-
ple) have (as yet undetected)
resistance. Of the 1000 people
who take the MTBDRsl test, 115
people will be correctly identi-
fied as having resistance (TPs)
. However, 35 people with re-
sistance will remain undetected;
their ‘ ‘ negative’’ test results will
be incorrect (FNs)
A diagnostic test does not al-
ways accurately identify all of
the people who do not have the
disease or condition in question
850 people (out of 1000 peo-
ple) do not have resistance. Of
the 1000 people who take the
MTBDRsl test, 846 of these peo-
ple will be correctly identified
as not having resistance (TNs)
. However, 4 people will be in-
correctly identified; their ‘ ‘ pos-
itive’’ test results will suggest
they have resistance (FPs)
1637 (14 studies) Quality of the evidence indicates
how likely it is that the accuracy
of the test will be substantially




23% 230 people (out of 1000 peo-
ple) have (as yet undetected)
resistance. Of the 1000 people
who take the MTBDRsl test, 177
people will be correctly identi-
fied as having resistance (TPs)
. However, 53 people with re-
sistance will remain undetected;
their ‘ ‘ negative’’ test results will
be incorrect (FNs)
770 people (out of 1000 peo-
ple) do not have resistance. Of
the 1000 people who take the
MTBDRsl test, 766 of these peo-
ple will be correctly identified
as not having resistance (TNs)
. However, 4 people will be in-
correctly identified; their ‘ ‘ pos-
itive’’ test results will suggest
they have resistance (FPs)
30% 300 people (out of 1000 peo-
ple) have (as yet undetected)
resistance. Of the 1000 people
who take the MTBDRsl test, 231
people will be correctly identi-
fied as having resistance (TPs)
. However, 69 people with re-
sistance will remain undetected;
700 people (out of 1000 peo-
ple) do not have resistance. Of
the 1000 people who take the
MTBDRsl test. 696 of these peo-
ple will be correctly identified
as not having resistance (TNs)
. However, 4 people will be in-
























































































































































































their ‘ ‘ negative’’ test results will
be incorrect (FNs)
itive’’ test results will suggest
they have resistance (FPs)
B. MTBDRsl for second-line injectable drugs by direct testing
Prevalence Sensitivity (95% CI)
94.4% (25.2 to 99.9)
Specificity (95% CI)
98.2% (88.9 to 99.7)
Number of participants (stud-
ies)
Quality of the evidence
(GRADE)*
15% A diagnostic test does not al-
ways accurately detect all of the
people who actually have the
disease or condition in question
150 people (out of 1000 peo-
ple) have (as yet undetected)
resistance. Of the 1000 people
who take the MTBDRsl test, 142
people will be correctly identi-
fied as having resistance (TPs)
. However, 8 people with re-
sistance will remain undetected;
their ‘ ‘ negative’’ test results will
be incorrect (FNs). There is con-
siderable uncertainty in these re-
sults. If the CIs are taken into ac-
count, then between 0 and 112
people might be missed (FNs)
A diagnostic test does not al-
ways accurately identify all of
the people who do not have the
disease or condition in question
850 people (out of 1000 peo-
ple) do not have resistance.
Of the 1000 people who take
the MTBDRsl test, 835 of these
people will be correctly iden-
tified as not having resistance
(TNs). However, 15 people will
be incorrectly identified; their
‘ ‘ positive’’ test results will sug-
gest they have resistance (FPs)
. There is considerable uncer-
tainty in these results. If the CIs
are taken into account, then be-
tween 3 and 94 people might be
misclassified as positive (FPs)
947 (6 studies) Quality of the evidence indicates
how likely it is that the accuracy
of the test will be substantially




23% 230 people (out of 1000 peo-
ple) have (as yet undetected)
resistance. Of the 1000 people
who take the MTBDRsl test, 217
people will be correctly identi-
fied as having resistance (TPs)
. However, 13 people with re-
sistance will remain undetected;
their ‘ ‘ negative’’ test results will
770 people (out of 1000 peo-
ple) do not have resistance.
Of the 1000 people who take
the MTBDRsl test, 756 of these
people will be correctly iden-
tified as not having resistance
(TNs). However, 14 people will
be incorrectly identified; their

























































































































































































be incorrect (FNs). There is con-
siderable uncertainty in these re-
sults. If the CIs are taken into ac-
count, then between 0 and 172
people might be missed (FNs)
gest they have resistance (FPs)
. There is considerable uncer-
tainty in these results. If the CIs
are taken into account, then be-
tween 2 and 85 people might be
misclassified as positive (FPs)
30% 300 people (out of 1000 peo-
ple) have (as yet undetected)
resistance. Of the 1000 people
who take the MTBDRsl test, 283
people will be correctly identi-
fied as having resistance (TPs)
. However, 17 people with re-
sistance will remain undetected;
their ‘ ‘ negative’’ test results will
be incorrect (FNs). There is con-
siderable uncertainty in these re-
sults. If the CIs are taken into ac-
count, then between 0 and 224
people might be missed (FNs)
700 people (out of 1000 peo-
ple) do not have resistance.
Of the 1000 people who take
the MTBDRsl test. 687 of these
people will be correctly iden-
tified as not having resistance
(TNs). However, 13 people will
be incorrectly identified; their
‘ ‘ positive’’ test results will sug-
gest they have resistance (FPs)
. There is considerable uncer-
tainty in these results. If the CIs
are taken into account, then be-
tween 2 and 78 people might be
misclassified as positive (FPs)
*We deducted one point for limitations and, for direct testing, two additional points for imprecision (considering the very wide 95% CI
for pooled sensitivity). We did not deduct points for indirectness; however we consider sensitivity and specificity to be surrogates for
patient-important outcomes and high accuracy does not mean that patients will get better.

























































































































































































Patients Patients or specimens of any age presumed to have resistance to any of the second-line TB drugs and those
with confirmed MDR-TB
Prior testing Patients who received MTBDRsl testing will first have received smear microscopy or culture (if smear-negative)
or both for the detection of TB and phenotypic or genotypic DST for resistance to first-line TB drugs
Settings Intermediate or central level laboratories
Index (new) test MTBDRsl assay
Reference standard Culture-based DST
Studies Cross-sectional and case control studies in which cases and controls were sampled from the same patient
population
A. MTBDRsl for XDR-TB by indirect testing
Prevalence Sensitivity (95% CI)
70.9% (42.9 to 88.8)
Specificity (95% CI)
98.8% (96.1 to 99.6)
Number of participants
(studies)
Quality of the evidence
(GRADE)*
8% A diagnostic test does not
always accurately detect
all of the people who ac-
tually have the disease or
condition in question
80 people (out of 1000
people) have (as yet un-
detected) XDR-TB. Of the
1000 people who take the
MTBDRsl test, 57 people
will be correctly identified
as having XDR-TB (TPs).
However, 23 people with
XDR-TB will remain un-
detected; their ‘ ‘ negative’’
test results will be incor-
rect (FNs)
A diagnostic test does not
always accurately identify
all of the people who do not
have the disease or condi-
tion in question
920 people (out of 1000
people) do not have XDR-
TB. Of the 1000 people
who take theMTBDRsl test,
909 of these people will
be correctly identified as
not having XDR-TB (TNs).
However, 11 people will be
incorrectly identified; their
‘ ‘ positive’’ test results will
suggest they have XDR-TB
(FPs)
880 (8 studies) Quality of the evidence in-
dicates how likely it is that
the accuracy of the test
will be substantially differ-




11% 110 people (out of 1000
people) have (as yet un-
detected) XDR-TB. Of the
1000 people who take the
MTBDRsl test, 78 people
will be correctly identified
as having XDR-TB (TPs).
However, 32 people with
XDR-TB will remain un-
detected; their ‘ ‘ negative’’
test results will be incor-
890 people (out of 1000
people) do not have XDR-
TB. Of the 1000 people
who take theMTBDRsl test,
879 of these people will
be correctly identified as
not having XDR-TB (TNs).
However, 11 people will be
incorrectly identified; their
‘ ‘ positive’’ test results will
suggest they have XDR-TB
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rect (FNs) (FPs)
B. MTBDRsl for XDR-TB, by direct testing, 644 participants (3 studies). There was considerable heterogeneity in accuracy
estimates and we did not perform a meta-analysis
*We deducted one point for limitations and one point for imprecision (considering the wide 95% CI for pooled sensitivity). We did not
deduct points for indirectness; however we consider sensitivity and specificity to be surrogates for patient-important outcomes and
high accuracy does not mean that patients will get better.
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D I S C U S S I O N
This systematic review found that, when used indirectly on cul-
ture isolates,MTBDRslhad higher pooled sensitivity for detection
of FQ resistance (83.1%) than for detection of SLID resistance
(76.9%). When used directly on smear-positive sputum speci-
mens, MTBDRsl had lower pooled sensitivity for FQ resistance
(85.1%) than for SLID resistance (94.4%); however the pooled
sensitivity for detection of SLID resistance was imprecise (95%CI
25.2 to 99.9). When SLID resistance was analysed for individual
drugs, the pooled sensitivitywas highest for amikacin (87.9%).For
detection of resistance to both FQs and SLIDs, pooled specificity
was high (> 97%). For detection of XDR-TB by indirect testing,
the pooled sensitivity of MTBDRsl was 70.9% and the pooled
specificity was 98.9%. The average sensitivities and specificities
of MTBDRsl for detection of resistance to FQs and SLIDs and
XDR-TB included in themeta-analyses are given in the ’Summary
of Findings’ tables (Summary of findings 1; Summary of findings
2; Summary of findings 3) and Table 3 Table 4 and Table 5.
When MTBDRsl accuracy was compared according to whether
the test was performed directly or indirectly, the sensitivities were
similar for FQ resistance and SLID resistance. Indirect MTBDRsl
testing for SLID resistance had slightly superior specificity com-
pared to direct testing (99.5% versus 98.2%). Indirect testing for
both FQ and SLID resistance had a lower rate of uninterpretable
MTBDRsl results than direct testing.
We performed subgroup analyses in which we compared the accu-
racy of MTBDRsl against different reference standards comprised
of phenotypic culture-based DST (the traditional gold standard)
or genetic sequencing. We looked at MTBDRsl accuracy against
each type of reference standard alone or in combination (where ei-
ther all specimens received both culture-based DST and sequenc-
ing). When used indirectly on culture isolates for detection of
FQ resistance, MTBDRsl had higher pooled sensitivity against ge-
netic sequencing than against culture-based DST (99.3% versus
83.1%). This suggests that MTBDRsl is sensitive for detecting
FQ resistance caused by mutations in gyrA (the only gene that is
targeted by MTBDRsl for detection of FQ resistance). However,
against culture-basedDST,MTBDRsl sensitivity for FQ resistance
was only 83.1% suggesting that just less than one in five cases may
be caused by mutations outside of gyrA, such as in gyrB, a gene
which is not targeted by MTBDRsl. Only two studies (Brossier
2010; Huang 2011) performed genetic sequencing for both gyrA
and gyrB and they reported sensitivity estimates of 84.6% and
100.0%, respectively.
Similarly, we found higher pooled sensitivity for SLID resistance
when MTBDRsl was evaluated against genetic sequencing rather
than culture-based DST (97.0% versus 76.9%). In this case, both
genetic sequencing and MTBDRsl only target the rrs gene for re-
sistance to SLIDs. This approach can potentially miss mutations
outside of this region that are responsible for SLID resistance. Us-
ing culture-based DST (sensitivity 76.9%), it appears that around
one in four cases of SLID-resistant TB may be caused by muta-
tions outside of rrs. The prevalence of these non-rrs mutations,
which can occur in regions such as tlyA, eis and gidB (Georghiou
2012), appears to bemost pronounced for kanamycin given the re-
duced sensitivity (66.9%) of MTBDRsl for resistance to this drug
compared to the other SLIDs (sensitivity of 87.9% and 79.5%
for amikacin and capreomycin, respectively, against culture-based
DST). The sensitivity of MTBDRsl for SLID resistance, and in
particular kanamycin resistance, is likely to vary according to the
genetic background of TB strains, where some may have a greater
frequency of resistance-causing mutations that fall outside of rrs
and different levels of cross-resistance within the SLIDs. When we
excluded a large study from Eastern Europe (Kontsevaya 2013),
both the sensitivity of MTBDRsl and the precision of our pooled
estimate improved.
We are aware of an unpublished Foundation for Innovative and
New Diagnostics-sponsored evaluation of MTBDRsl at the Uni-
versity of Cape Town (K. Dheda, personal communication). For
the direct detection of drug resistance compared to culture-based
DST as a reference standard, this work reported a sensitivity and
specificity of 79.2% (38/48) and 86.5% (45/52), respectively, for
the detection of resistance to ofloxacin, and a sensitivity and speci-
ficity of 72.9% (35/48) and 94.2% (49/52) respectively for the
detection of resistance to amikacin.When performed indirectly on
culture isolates, the sensitivity and specificity for the detection of
ofloxacin resistance were 72.3% (115/159) and 99.0% (100/101)
respectively, and 76.6% (125/157) and 98.0% (99/101) respec-
tively for amikacin resistance, when compared to culture-based
DST as a reference standard.
MTBDRsl is the only commercially-available rapid molecular test
for the detection of resistance to the FQs, SLIDs and XDR-TB.
Alternative phenotypic methods of DST for TB may take sev-
eral weeks (Barnard 2012; Lopez-Roa 2012) to several months
(Said 2012; Tukvadze 2014). This lengthy turnaround time, dur-
ing which the patientmay be on ineffective therapy and contribute
to ongoing TB transmission, is further exacerbated by the need to
first grow a M. tuberculosis isolate (which itself may take two to
six weeks). Two systematic reviews ofMTBDRsl exist (Feng 2013;
WHO 2013b). As in our review, WHO 2013b used a random-
effects meta-analysis model and arrived at similar summary esti-
mates, generally within three percentage points of those described
in our review. Feng 2013 used a fixed-effects model and reported
accuracy estimates for kanamycin and capreomycin resistance that
were substantially lower than the ones we found. Our review in-
cluded additional studies not included in these previous reviews.
Key questions remain regarding test accuracy and potential sources
of heterogeneity, including risk of bias assessment, type of testing
(indirect versus direct testing) and reference standard (for example,
culture-based DST versus genetic sequencing). We address several
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of these questions in this review. Although we intended to inves-
tigate whether the observed test accuracy varied between studies
according to HIV infection, specimen condition (frozen versus
fresh), specimen type (induced sputum or extrapulmonary speci-
men), the drug concentration used in culture-based DST (studies
that used WHO-recommended concentrations versus those that
did not) or population (patients suspected of having MDR-TB
or XDR-TB), there were unfortunately insufficient data to per-
form these additional analyses for each target condition. We were
also unable to examine sources of heterogeneity for detection of
XDR-TB due to insufficient data. More comparative diagnostic
accuracy data are needed from strains from different geographic
regions (for example, Eastern Europe), where resistance-causing
mutations that fall outside of the genes targeted by MTBDRsl are
less common than in drug-resistant strains from South Africa, for
example. Such future research should include genetic sequencing
as a reference standard that targets all known resistance-determin-
ing mutations and not just those detectable using MTBDRsl.
Summary of main results
Themain results are presented in the ’Summary of findings’ tables:
• When used indirectly on culture isolates, MTBDRsl
detected 83.1% of FQ-resistant cases with high specificity
(97.7%) when culture-based DST was used as a reference
standard. When evaluated against genetic testing as a reference
standard, the sensitivity and specificity were 99.3% and 99.7%,
respectively.
• When used directly on smear-positive sputum specimens,
MTBDRsl detected 85.1% of FQ-resistant cases with high
specificity (98.2%).
• When used indirectly on culture isolates, MTBDRsl
detected 76.9% of SLID resistant cases with high specificity
(99.5%) when culture-based DST was used as a reference
standard. The pooled sensitivities for resistance to amikacin,
kanamycin and capreomycin were 87.9%, 66.9% and 79.5%,
respectively. The sensitivity and specificity for SLID resistance
evaluated against genetic testing as a reference standard were
97.0% and 99.5%, respectively.
• When used directly on smear-positive sputum specimens,
MTBDRsl detected 94.4% of SLID-resistant cases with high
specificity (98.2%). The pooled sensitivities for resistance to
amikacin, kanamycin and capreomycin were 97.3%, 72.1% and
68.7%, respectively.
• When used indirectly on culture isolates, MTBDRsl
detected 70.9% of XDR-TB cases with high specificity (98.8%)
when culture-based DST was used as a reference standard.
The proportion of indeterminate results was lower when
MTBDRsl was performed indirectly rather than directly (0.2%
versus 1.9% for FQ resistance, P < 0.001; 0.4% versus 6.1% for
SLID resistance, P < 0.001; 0.1% versus 1.8% for XDR-TB resis-
tance, P = 0.002).
Application of the meta-analysis to a hypothetical
cohort
’Summary of findings’ tables (Summary of findings 1; Summary of
findings 2; Summary of findings 3) summarize the review findings
by applying the results to a hypothetical cohort of 1000 individ-
uals with MDR-TB thought to have resistance to a FQ, or SLID,
or both. We present scenarios, based on WHO estimates (WHO
2013a), with the prevalence of FQ resistance varying from 12% to
17% to 21%, that of SLID resistance varying from 15% to 23%
to 30%, and that of XDR-TB varying from 8% to 11%. The con-
sequences of FP results are likely patient anxiety, morbidity from
additional testing, possible delay in further diagnostic evaluation,
and prolonged and unnecessary treatment with drugs that may
have lower bacteriocidal activity than second-line regimens and
often have serious side effects. The consequences of FN results are
an increased risk of patient morbidity and mortality, and contin-
ued risk of community transmission of drug-resistant TB.
1A. Indirect testing for fluoroquinolone resistance,
MTBDRsl performed on culture isolates
FQ resistance prevalence of 12%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 120 patients have FQ-resistant TB, then
MTBDRsl would be expected to miss between 20 and 26 cases
and falsely diagnose between eight and 50 cases.
FQ resistance prevalence of 17%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 170 patients have FQ-resistant TB, then
MTBDRsl would be expected to miss 23 and 26 cases and falsely
diagnose between seven and 47 cases.
FQ resistance prevalence of 21%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 210 patients have FQ-resistant TB, then
MTBDRsl would be expected to miss between 28 and 45 cases
and falsely diagnose between seven and 45 cases.
1B. Direct testing for fluoroquinolone resistance, MTBDRsl
performed on sputum specimens
FQ resistance prevalence of 12%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 120 patients have FQ-resistant TB, then
MTBDRsl would be expected to miss between nine and 34 cases
and falsely diagnose between nine and 28 cases.
FQ resistance prevalence of 17%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 170 patients have FQ-resistant TB, then
MTBDRsl would be expected to miss between 12 and 48 cases
and falsely diagnose between eight and 27 cases.
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FQ resistance prevalence of 21%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 210 patients have FQ-resistant TB, then
MTBDRsl would be expected to miss between 15 and 59 cases
and falsely diagnose between eight and 25 cases.
2A. Indirect testing for SLID resistance, MTBDRsl
performed on culture isolates
SLID resistance prevalence of 15%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 150 patients have SLID resistant TB, then
MTBDRsl would be expected to miss between 19 and 58 cases
and falsely diagnose between one and 25 cases.
SLID resistance prevalence of 23%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 230 patients have SLID resistant TB, then
MTBDRsl would be expected to miss between 29 and 89 cases
and falsely diagnose between one and 22 cases.
SLID resistance prevalence of 30%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 300 patients have SLID resistant TB, then
MTBDRsl would be expected to miss between 37 and 117 cases
and falsely diagnose between one and 20 cases.
2B. Direct testing for SLID resistance, MTBDRsl performed
on sputum specimens
SLID resistance prevalence of 15%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 150 patients have SLID resistant TB, then
MTBDRsl would be expected to miss between zero and 112 cases
and falsely diagnose between three and 94 cases.
SLID resistance prevalence of 23%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 230 patients have SLID resistant TB, then
MTBDRsl would be expected to miss between zero and 172 cases
and falsely diagnose between two and 85 cases.
SLID resistance prevalence of 30%: if the pooled estimates for
MTBDRsl are applied to a hypothetical cohort of 1000 pa-
tients with TB, where 300 patients have SLID resistant TB, then
MTBDRsl would be expected to miss between zero and 224 cases
and falsely diagnose between two and 78 cases.
3A. Indirect testing for XDR-TB resistance, MTBDRsl
performed on culture isolates
XDR-TB prevalence of 8%: if the pooled estimates for MTBDRsl
are applied to a hypothetical cohort of 1000 patients with TB,
where 80 patients have XDR-TB, then MTBDRsl would be ex-
pected to miss between nine and 46 cases and falsely diagnose be-
tween four and 36 cases.
XDR-TBprevalence of 11%: if the pooled estimates forMTBDRsl
are applied to a hypothetical cohort of 1000 patients with TB,
where 110 patients have XDR-TB, then MTBDRsl would be ex-
pected to miss between 12 and 63 cases and falsely diagnose be-
tween four and 35 cases.
Strengths and weaknesses of the review
The results of this Cochrane Review are based on strict and careful
searching, study inclusion and data extraction. The strength of
this review is that it allows an assessment of different methods of
testing (indirect versus direct) and different reference standards.
Completeness of evidence
This is a reasonably complete data set. We included any non-
English studies we found. We excluded seven studies that were not
diagnostic accuracy studies and 13 studies that were conference
abstracts (however, several of these were included in the form of
full-length published papers). We did not include unpublished
data. Studies of diagnostic test accuracy tend to be poorly indexed
(Whiting 2005) and we may therefore have missed some studies
despite the comprehensive search.
Accuracy of the reference standards used
For our primary analysis, we used phenotypic culture-based DST.
This was the most frequently deployed reference standard in the
included studies. Although considered to be the ’gold standard’ for
drug-resistant TB, culture-based DST is not 100% accurate for
detection of drug resistance, in particular with respect to detection
of second-line drug resistance. We also determined MTBDRsl ac-
curacy using genetic testing (gene sequencing of loci known to
be associated with drug resistance) and both genetic testing and
culture-based DST as reference standards. Many TB experts con-
sider genetic sequencing to be the best available reference standard,
provided it encompasses all the possible resistance determining
regions. In addition, we determined the accuracy of MTBDRsl
against a fourth reference standard, where genetic testing was
only performed as part of a discrepant analysis in culture-DST-
MTBDRsl discordant specimens. However, in most cases we were
unable to determine summary estimates due to the small number
of studies and therefore were unable to compare MTBDRsl accu-
racy estimates using this reference standard with those obtained
using culture-based DST, or genetic sequencing, or both, as the
reference standard.
Quality and quality of reporting of the included
studies
We judged nine of the 21 included studies as having high risk
of bias for patient selection (either due to a case-control design,
or enrolment by convenience, or both). Otherwise, for the other
QUADAS-2 domains, we considered at least half of the included
studies to have low risk of bias. We noted that seven studies (33%)
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did not provide information about whether the MTBDRsl results
were read in the absence of knowledge of the results of the refer-
ence standard. Overall, we had low concern about applicability.
In addition, seven studies (33%) had industry involvement.
Interpretability of subgroup analyses
We performed subgroup analyses according to type of testing and
reference standard used and for the individual drugs in the FQ
and SLID drug classes. For comparing test accuracy, we only per-
formed analyses that had at least four studies in a given subgroup.
We performed statistical testing and provided P values where ap-
propriate. We performed both indirect and direct comparisons.
Completeness and relevance of the review
There are no other commercially-available tests for resistance be-
yondMDR-TB. Several products, such as the GeneXpert®XDR-
TB cartridge (Cepheid, USA), are expected to be commercially
available in 2015. Our review is the most complete analysis of the
diagnostic accuracy of the MTBDRsl test to date.
Unpublished data
We did not include unpublished studies in the review, though we
regularly checked the TB literature to see if studies we identified as
abstracts had been published. It is our experience that unpublished
diagnostic accuracy data frequently changes after publication. In
addition, primary study authors in our field rarely give permission
to publish their unpublished data. We have nevertheless related
our findings in the Discussion to those of the largest unpublished
study that we are aware of.
Applicability of findings to the review question
We found MTBDRsl to have moderate sensitivity and excellent
specificity for the detection of FQ resistance, SLID resistance and
XDR-TB. The proportion of false-negative results is concerning
and means that the test will likely only be usable in clinical prac-
tice as a “rule-in” test for drug resistance, with further DST being
required in patients who have a susceptible MTBDRsl result. The
local genetic background of drug-resistant strains (which, for ex-
ample,may have a greater frequency of kanamycin-resistance caus-
ing mutations outside of rrs) also needs to be considered by test
operators. In contrast, the proportion of false-positive results was
small as the specificity was excellent. We found no significant dif-
ferences in accuracy between indirect testing on isolates and direct
testing on smear-positive sputum specimens. MTBDRsl accuracy
was generally greater when measured against a reference standard
that included genetic testing. However, such genetic testing was
only limited to the genes the MTBDRsl targeted and did not de-
tect mutations outside of these genes that may cause phenotypic
drug resistance. For some subgroup analyses (for example, patient
characteristics), there were insufficient data to analyse differences.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In adults presumed to have resistance to second-line TB drugs,
MTBDRsl has moderate sensitivity and excellent specificity. Ap-
proximately 25% patients with XDR-TB will be missed by
MTBDRsl and 0.01% of patients without XDR-TB will be falsely
diagnosed as having XDR-TB. Where possible, MTBDRsl should
be performed directly on smear-positive sputum, as the accuracy
is similar to when it is performed indirectly (on culture isolates)
and there is no need to wait several weeks for the culture to grow
(although the rate of uninterpretable results is marginally higher
when the test is performed directly). Therefore, given its rule-in
value and rapidity, MTBDRsl may be used as an initial test for sec-
ond-line drug resistance.However, phenotypic culture-basedDST
should still be used for the downstream investigation of patients
who have susceptible MTBDRsl results. The use of MTBDRsl in
routine care should improve the time to the diagnosis of drug-
resistant TB and could thereby lead to the earlier initiation of
appropriate patient therapy and improvements in patient health,
provided the necessary accompanying improvements in capacity
and infrastructure are made.
Implications for research
Future studies should assess the diagnostic accuracy of MTBDRsl
when performed in different laboratory settings and patients (for
example, in people living with HIV). The test’s accuracy should be
examined and compared using strains from different geographical
regions, as these are likely to have different frequencies of resis-
tance-causing mutations that fall outside of the genes targeted by
MTBDRsl (and therefore MTBDRsl will likely having different
sensitivities for each condition in these strains). Future molecular
tests for FQ and SLID resistance should have more genetic targets
than just gyrA and rrs. Studies are also needed to assess the effect of
MTBDRsl implementation on time-to-treatment, patient health
and cost-effectiveness.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ajbani 2012
Study characteristics
Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: India
2. World Bank classification of country: middle/low
3. Type of lab: hospital
4. Type of patients: confirmed MDR-TB cases
5. Patients were smear-positive (n = 170)
Index tests 1. Manufacturer involvement: yes, in design, analysis or manuscript production
2. Type of testing: direct
3. Type of specimens: smear-positive
4. Specimen treatment: NALC-NaOH
5. Specimen condition: frozen
6. Duration of freezing: < 1 year
Target condition and reference
standard(s)
1. Culture (Liquid; MGIT 960) used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL) and moxifloxacin (0.25 µg/mL)
3. SLIDs: amikacin (1 µg/mL), capreomycin (2.5 µg/mL) and kanamycin (2.5 µg/mL)
4. Discrepant analysis: yes, with sequencing




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Ajbani 2012 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No





Patient sampling Cross-sectional designwith convenience-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: South Africa
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases, confirmed RIF monoR, confirmed INHmonoR
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Barnard 2012 (Continued)
5. Patients were smear-positive (n = 516; excluding EPTB)
Index tests 1. Manufacturer involvement: yes, reduced price
2. Type of testing: direct
3. Type of specimens: smear-positive
4. Specimen treatment: NALC-NaOH
5. Specimen condition: fresh
6. Tested after storage at room temperature or refrigerated within 48 hours of collection
Target condition and reference
standard(s)
1. Culture (solid; AP method on 7H11) used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: amikacin (4 µg/mL)
4. Discrepant analysis: yes, with sequencing
Flow and timing Uninterpretable results reported: yes
Comparative
Notes • Reported performance on EPTB specimens
• Reported on the utility of the index test on specimens that were culture-contaminated (and
hence could not receive a phenotypic DST)
• Reported on time-to-result
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No





Patient sampling Case-control design with unknown mechanism of enrolment of participants, prospective data col-
lection
Patient characteristics and set-
ting
1. Country of origin: France
2. World Bank classification of country: high
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases, confirmed XDR-TB cases, confirmed DS-TB
patients
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (Solid; agar proportion method on LJ) and sequencing used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: amikacin (20 µg/mL), kanamycin (20 µg/mL), capreomycin (20 µg/mL)
4. Genes sequenced for FQ: gyrA and gyrB
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Brossier 2010 (Continued)
5. Genes sequenced for SLIDs: rrs
6. Discrepant analysis: no




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional design with unknown mechanism of enrolment of participants, unknown direction
of data collection
Patient characteristics and set-
ting
1. Country of origin: Japan
2. World Bank classification of country: high
3. Type of lab: reference
4. Type of patients: unknown
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (solid; Ogawa solid culture for FQs, unclear for SLIDs) and sequencing used for FQ,
SLID
2. FQ drugs: levofloxacin (1 µg/mL)
3. SLIDs: amikacin (unknown concentration), kanamycin (unknown concentration),
capreomycin (unknown concentration)
4. Genes sequenced for FQ: gyrA
5. Genes sequenced for SLIDs: rrs
6. Discrepant analysis: no
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Chikamatsu 2012 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Chikamatsu 2012 (Continued)





Patient sampling Cross-sectional designwith convenience-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: China
2. World Bank classification of country: middle/low
3. Type of lab: research
4. Type of patients: confirmed MDR-TB patients and confirmed XDR-TB patients
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (liquid; MGIT960)
2. FQ drugs: ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL)
3. SLIDs: amikacin (1 µg/mL)
4. Discrepant analysis: no




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
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Fan 2011 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional design with random enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Colombia
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed DS-TB, MDR-TB, MDR-TB with some known second-line
resistance and XDR-TB patients
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Ferro 2013 (Continued)
Index tests 1. Manufacturer involvement: yes
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture based DST (solid, 7h10)
2. FQ drugs: moxifloxacin 2 µg/mL
3. SLIDS: amikacin 5 µg/mL, kanamycin 5 µg/mL
4. No XDR information reported
5. There was no discrepant analysis




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Ferro 2013 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Case-control design with the random enrolment of participants, prospective data collection for
clinical specimens, retrospective for culture isolates
Patient characteristics and set-
ting
1. Country of origin: Germany
2. World Bank classification of country: high
3. Type of lab: reference
4. Type of patients: confirmed XDR-TB cases, confirmed DS-TB cases
5. The specimens tested were smear positive and smear negative
Index tests 1. Manufacturer involvement: yes, donation of tests
2. Type of testing: direct and indirect
3. Type of specimens: smear-positive
4. Specimen treatment: NALC-NaOH
5. Specimen condition: frozen
6. Duration of freezing: > 1 year
Target condition and reference
standard(s)
1. Culture (liquid and solid; MGIT 960 and LJ) and sequencing used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL for liquid)
3. SLIDs: amikacin (1 µg/mL for liquid) and capreomycin (2.5 µg/mL for liquid)
4. Genes sequenced for FQ: gyrA
5. Genes sequenced for SLIDs: rrs
6. Discrepant analysis: no
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Hillemann 2009 (Continued)




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
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Hillemann 2009 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: China
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (solid; 7H11) and sequencing used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: amikacin (1 µg/mL), kanamycin (6 µg/mL) and capreomycin (10 µg/mL)
4. Genes sequenced for FQ: gyrA and gyrB
5. Genes sequenced for SLIDs: rrs and eis
6. Discrepant analysis: no




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Huang 2011 (Continued)
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Case control design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Estonia
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases, confirmed XDR-TB cases and confirmed DS-
TB cases
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (liquid; MGIT 960) used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: amikacin (1 µg/mL), kanamycin (5 µg/mL) and capreomycin (2.5 µg/mL)
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings: the interpretability of the Genotype® MTBDRsl assay was high, varying between
98.0% and 100% for the first reading and between 95.5% and 100% for the second reading (Table
3)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Ignatyeva 2012 (Continued)




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: China
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB patients and confirmed XDR-TB patients
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
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Jin 2013 (Continued)
Target condition and reference
standard(s)
1. Culture (solid; LJ) and sequencing used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: kanamycin (10 µg/mL)
4. Genes sequenced for FQ: gyrA
5. Genes sequenced for SLIDs: rrs
6. Discrepant analysis: no




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Jin 2013 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Case control design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Vietnam
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases with FQ resistance, confirmed FQ
monoresistant cases
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (solid; LJ) used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: kanamycin (20 µg/mL), not WHO recommended critical concentrations for LJ solid
culture
4. Discrepant analysis: yes
Flow and timing Uninterpretable results reported: yes
Comparative
Notes
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Kiet 2010 (Continued)
Did all patients receive the same
reference standard?
No





Patient sampling Cross sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: United Kingdom
2. World Bank classification of country: high
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (liquid; MGIT960) used for FQ
2. FQ drugs: Ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL)
3. Discrepant analysis: no




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Kontsevaya 2011 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross sectional design with consecutive enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Russia
2. World Bank classification of country: Middle/low
3. Type of lab: unknown
4. Type of patients: confirmed MDR-TB cases
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Kontsevaya 2013 (Continued)
5. Median age: 35
6. All HIV-infected (n = 90)
7. Previous TB: 38/90
8. Male: 71/90
Index tests 1. Manufacturer involvement: no
2. Type of testing: direct
3. Type of specimens: smear-positive
4. Specimen treatment: unknown
5. Specimen condition: unknown
6. Duration of freezing: unknown
Target condition and reference
standard(s)
1. Culture (Liquid; MGIT960) used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL) and moxifloxacin (0.25 µg/mL)
3. SLIDs: kanamycin (5 µg/mL), amikacin (1 µg/mL) and capreomycin (2.5 µg/mL)
4. Discrepant analysis: no
Flow and timing Uninterpretable results reported: no
Comparative
Notes Other findings: analysis of test performance stratified according to sputum smear positivity showed
that the test readability for individual drugs and their drug groups ranged from 80.0% to 100.0%,
with the lowest for specimens graded 1 (Table 5). Within this group of specimens, lower readability
rates were observed for the AG/CP group of drugs (n 3; 20.0% of tests failed), with higher readability
rates for FQ and ethambutol. Similar trends were observed in specimens graded 2 and 3 (Fig. 1).
Total agreement between the molecular assay and phenotypic DST was the highest (84.1%) for
FQs and lowest (23.5%) for the injectable drugs
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
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Kontsevaya 2013 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional designwith convenience-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Spain
2. World Bank classification of country: high
3. Type of lab: hospital
4. Type of patients: confirmed MDR-TB cases
5. Smear-positive patients whose specimens were tested directed: 49/54
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Lacoma 2012 (Continued)
Index tests 1. Manufacturer involvement: no
2. Type of testing: direct and indirect
3. Type of specimens: smear-positive and smear negative
4. Specimen treatment: NALC-NaOH
5. Specimen condition: frozen
6. Duration of freezing: > 1 year
Target condition and reference
standard(s)
1. Culture (liquid; BACTEC460TB) used for FQ, SLID
2. FQ drugs: moxifloxacin (0.5 µg/mL)
3. SLIDs: kanamycin (5 µg/mL) and capreomycin (1.25 µg/mL)
4. Discrepant analysis: yes (for indirect testing only)




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
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Lacoma 2012 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No





Patient sampling Cross-sectional designwith convenience-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Spain
2. World Bank classification of country: high
3. Type of lab: hospital
4. Type of patients: confirmed MDR-TB cases
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (solid and liquid; 7H11 and MGIT 960) used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: amikacin (4 µg/mL)
4. Discrepant analysis: yes
Flow and timing Uninterpretable results reported: yes
Comparative
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Lopez-Roa 2012 (Continued)
Notes Other findings: the turnaround time for agar proportion, MGIT 960 and GenoType® MTBDRsl
were, respectively, 21 days, 8 days and 8 hours.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
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Lopez-Roa 2012 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No





Patient sampling Isolates: case-controlled design with consecutive enrolment of participants, prospective data collec-
tion
Specimens: cross-sectional design with consecutive enrolment of participants, prospective data col-
lection
Patient characteristics and set-
ting
1. Country of origin: Italy
2. World Bank classification of country: high
3. Type of lab: hospital
4. Type of patients: confirmed MDR-TB cases, confirmed XDR-TB cases, confirmed MDR-
TBs with some known 2nd line resistance
Index tests 1. Manufacturer involvement: yes, donation of test
2. Type of testing: direct and indirect
3. Type of specimens: smear-positive
4. Specimen treatment: NALC-NaOH
5. Specimen condition: frozen
6. Duration of freezing: > 1 year
Target condition and reference
standard(s)
1. Culture (solid; 7H11) and sequencing used for FQ, SLID
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: kanamycin (5 µg/mL) and capreomycin (10 µg/mL)
4. Discrepant analysis: no
5. Genes for FQ: gyrA
6. Genes for SLIDs: rrs
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings:
NPV for SLID is higher in Beijing strains
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Miotto 2012 (Continued)
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional design with consecutive-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: South Africa
2. World Bank classification of country: middle/low
3. Type of lab: research
4. Type of patients: confirmed MDR-TB cases
Index tests 1. Manufacturer involvement: yes, financial support.
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (solid; 7H11)
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: kanamycin (5 µg/mL) and capreomycin (10 µg/mL). Not the WHO critical
concentrations for SLIDs.
4. Discrepant analysis: no
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings: turnaround times for DST ranged from 6 to 21 days (median 11) for the agar
proportion method and from 2 to 3 days (median 2) for the MTBDRsl assay. DST results of the
MTBDRsl assay as compared to the agar proportion method are shown in Table 2
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Said 2012 (Continued)




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Patient sampling Cross-sectional design with consecutive-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Cambodia
2. World Bank classification of country: middle/low
3. Type of lab: unknown
4. Type of patients: confirmed MDR-TB cases
Index tests 1. Manufacturer involvement: yes, donation of tests
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Sequencing used for reference standard
2. FQ genes: gyra
3. SLID genes: rrs
4. Discrepant analysis: no
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Other findings: spoligotyping results showed that the majority of MDR strains belonged to the
Beijing family (57/101, 56%) or were Beijing like (2/101, 2%). This percentage is higher in
MDR FQ-R strains (10/14, 71%). This confirms that Beijing strains are more prone to accumulate
antibiotic resistances
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Surcouf 2011 (Continued)




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional design with consecutive-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Georgia
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases
Index tests 1. Manufacturer involvement: no
2. Type of testing: direct
Target condition and reference
standard(s)
1. Culture based DST, LJ
2. FQ: ofloxacin 2 µg/mL
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Tukvadze 2014 (Continued)
3. SLIDS: capreomycin 40 µg/mL; kanamycin 30 µg/mL
4. There was no discrepant analysis
5. All reported XDR resistance




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes





Patient sampling Cross-sectional design with convenience-based enrolment of participants, retrospective data collec-
tion
Patient characteristics and set-
ting
1. Country of origin: Netherlands
2. World Bank classification of country: high
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases, confirmed MDR-TBs with some known
second-line resistance
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (solid; 7H10)
2. FQ drugs: moxifloxacin (1 µg/mL)
3. SLIDs: amikacin (5 µg/mL) and capreomycin (10 µg/mL). WHO critical concentrations not
used for 7H10 solid culture
4. Discrepant analysis: no
Flow and timing Uninterpretable results reported: yes
Comparative
Notes Relevant clinical information? unclear
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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van Ingen 2010 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No




DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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van Ingen 2010 (Continued)
Zivanovic 2012
Study characteristics
Patient sampling Cross-sectional design with consecutive-based enrolment of participants, prospective data collection
Patient characteristics and set-
ting
1. Country of origin: Serbia
2. World Bank classification of country: middle/low
3. Type of lab: reference
4. Type of patients: confirmed MDR-TB cases
Index tests 1. Manufacturer involvement: no
2. Type of testing: indirect
Target condition and reference
standard(s)
1. Culture (solid and liquid; LJ and MGIT960)
2. FQ drugs: ofloxacin (2 µg/mL)
3. SLIDs: amikacin (1 µg/mL for MGIT) and capreomycin (2.5 µg/mL for MGIT)
4. Discrepant analysis: no




Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes




DOMAIN 2: Index Test All tests
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Zivanovic 2012 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes




DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bantouna 2011 Conference abstract.
Bergvala 2010 Technical. Not a diagnostic accuracy study.
Brossier 2010a Conference abstract.
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Choi 2010 Technical. Not a diagnostic accuracy study.
Fallico 2012 Conference abstract.
Felkel 2013 Technical. No diagnostic data for FQs, SLIDs or XDR-TB.
Festoso 2011 Conference abstract.
Gkaravela 2012 Conference abstract.
Iem 2013 Technical. Only 1 case of second-line resistance.
Jang 2011 Conference abstract.
Karabela 2007 Conference abstract.
Kontos 2011 Conference abstract.
Kontos 2012 Conference abstract.
Lemus 2011 Conference abstract.
López-Roa 2010 Conference abstract.
Singh 2013 Technical. No information on resistance to the pre-specified FQs and no cases susceptible to the SLIDs
Tessema 2012a Technical. No information on resistance to FQs, SLIDs or XDR-TB
Tessema 2012b Technical. No information on resistance to FQs, SLIDs or XDR-TB
Totten 2011 Conference abstract.
Zhang 2011 Conference abstract.
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D A T A
Presented below are all the data for all of the tests entered into the review.






1 Indirect, FQ, culture 16 1766
2 Indirect, Ofl, culture 11 1544
3 Indirect, Mx, culture 4 222
4 Indirect, SLID, culture 14 1637
5 Indirect, Ak, culture 9 1017
6 Indirect, Kn, culture 9 1342
7 Indirect, Cm, culture 10 1406
8 Indirect, XDR, culture 8 880
9 Indirect, FQ, sequencing 7 974
10 Indirect, SLID, sequencing 6 873
11 Indirect, XDR, sequencing 3 541
12 Indirect, FQ, sequencing and
culture
7 1211
13 Indirect, SLID, sequencing and
culture
7 1491
14 Indirect, XDR, sequencing and
culture
2 435
15 Indirect, FQ, culture followed
by sequencing of discrepants
3 427
16 Indirect, SLID, culture
followed by sequencing of
discrepants
3 619
17 Direct, FQ, culture 7 1033
18 Direct, Ofl, culture 3 622
19 Direct, SLID, culture 6 947
20 Direct, Ak, culture 4 803
21 Direct, Kn, culture 4 418
22 Direct, Cm, culture 4 425
23 Direct, XDR, culture 3 644
24 Direct, FQ, culture followed by
sequencing of discrepants
2 685
25 Direct, SLID, culture followed
by sequencing of discrepants
2 666
26 Direct, XDR, culture followed
by sequencing of discrepants
1 516
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Test 1. Indirect, FQ, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 1 Indirect, FQ, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 21 1 3 27 0.88 [ 0.68, 0.97 ] 0.96 [ 0.82, 1.00 ]
Chikamatsu 2012 16 1 4 25 0.80 [ 0.56, 0.94 ] 0.96 [ 0.80, 1.00 ]
Fan 2011 49 3 3 39 0.94 [ 0.84, 0.99 ] 0.93 [ 0.81, 0.99 ]
Ferro 2013 3 8 0 62 1.00 [ 0.29, 1.00 ] 0.89 [ 0.79, 0.95 ]
Hillemann 2009 29 0 3 74 0.91 [ 0.75, 0.98 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 11 160 0.85 [ 0.75, 0.92 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 69 7 12 92 0.85 [ 0.76, 0.92 ] 0.93 [ 0.86, 0.97 ]
Jin 2013 111 11 26 113 0.81 [ 0.73, 0.87 ] 0.91 [ 0.85, 0.95 ]
Kiet 2010 31 0 10 21 0.76 [ 0.60, 0.88 ] 1.00 [ 0.84, 1.00 ]
Kontsevaya 2011 25 0 4 19 0.86 [ 0.68, 0.96 ] 1.00 [ 0.82, 1.00 ]
Lacoma 2012 4 5 3 17 0.57 [ 0.18, 0.90 ] 0.77 [ 0.55, 0.92 ]
Lopez-Roa 2012 5 0 1 20 0.83 [ 0.36, 1.00 ] 1.00 [ 0.83, 1.00 ]
Miotto 2012 42 1 15 116 0.74 [ 0.60, 0.84 ] 0.99 [ 0.95, 1.00 ]
Said 2012 26 7 11 292 0.70 [ 0.53, 0.84 ] 0.98 [ 0.95, 0.99 ]
van Ingen 2010 5 0 0 21 1.00 [ 0.48, 1.00 ] 1.00 [ 0.84, 1.00 ]
Zivanovic 2012 5 0 0 14 1.00 [ 0.48, 1.00 ] 1.00 [ 0.77, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Indirect, Ofl, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 2 Indirect, Ofl, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 21 1 3 27 0.88 [ 0.68, 0.97 ] 0.96 [ 0.82, 1.00 ]
Fan 2011 48 4 3 39 0.94 [ 0.84, 0.99 ] 0.91 [ 0.78, 0.97 ]
Hillemann 2009 29 0 3 74 0.91 [ 0.75, 0.98 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 11 160 0.85 [ 0.75, 0.92 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 69 7 12 92 0.85 [ 0.76, 0.92 ] 0.93 [ 0.86, 0.97 ]
Jin 2013 111 11 26 113 0.81 [ 0.73, 0.87 ] 0.91 [ 0.85, 0.95 ]
Kiet 2010 31 0 10 21 0.76 [ 0.60, 0.88 ] 1.00 [ 0.84, 1.00 ]
Lopez-Roa 2012 5 0 1 20 0.83 [ 0.36, 1.00 ] 1.00 [ 0.83, 1.00 ]
Miotto 2012 42 1 15 116 0.74 [ 0.60, 0.84 ] 0.99 [ 0.95, 1.00 ]
Said 2012 26 7 11 292 0.70 [ 0.53, 0.84 ] 0.98 [ 0.95, 0.99 ]
Zivanovic 2012 5 0 0 14 1.00 [ 0.48, 1.00 ] 1.00 [ 0.77, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Indirect, Mx, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 3 Indirect, Mx, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Fan 2011 49 3 3 39 0.94 [ 0.84, 0.99 ] 0.93 [ 0.81, 0.99 ]
Ferro 2013 3 8 0 62 1.00 [ 0.29, 1.00 ] 0.89 [ 0.79, 0.95 ]
Lacoma 2012 4 5 3 17 0.57 [ 0.18, 0.90 ] 0.77 [ 0.55, 0.92 ]
van Ingen 2010 5 0 0 21 1.00 [ 0.48, 1.00 ] 1.00 [ 0.84, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Indirect, SLID, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 4 Indirect, SLID, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 11 0 4 37 0.73 [ 0.45, 0.92 ] 1.00 [ 0.91, 1.00 ]
Chikamatsu 2012 10 0 8 28 0.56 [ 0.31, 0.78 ] 1.00 [ 0.88, 1.00 ]
Fan 2011 13 1 3 77 0.81 [ 0.54, 0.96 ] 0.99 [ 0.93, 1.00 ]
Ferro 2013 4 0 0 18 1.00 [ 0.40, 1.00 ] 1.00 [ 0.81, 1.00 ]
Hillemann 2009 40 0 6 60 0.87 [ 0.74, 0.95 ] 1.00 [ 0.94, 1.00 ]
Huang 2011 16 0 3 215 0.84 [ 0.60, 0.97 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 37 2 55 87 0.40 [ 0.30, 0.51 ] 0.98 [ 0.92, 1.00 ]
Jin 2013 48 9 24 180 0.67 [ 0.55, 0.77 ] 0.95 [ 0.91, 0.98 ]
Kiet 2010 5 0 0 57 1.00 [ 0.48, 1.00 ] 1.00 [ 0.94, 1.00 ]
Lacoma 2012 5 3 0 19 1.00 [ 0.48, 1.00 ] 0.86 [ 0.65, 0.97 ]
Miotto 2012 60 0 24 90 0.71 [ 0.61, 0.81 ] 1.00 [ 0.96, 1.00 ]
Said 2012 7 4 21 300 0.25 [ 0.11, 0.45 ] 0.99 [ 0.97, 1.00 ]
van Ingen 2010 6 0 0 21 1.00 [ 0.54, 1.00 ] 1.00 [ 0.84, 1.00 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Indirect, Ak, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 5 Indirect, Ak, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 10 0 0 42 1.00 [ 0.69, 1.00 ] 1.00 [ 0.92, 1.00 ]
Fan 2011 13 1 3 77 0.81 [ 0.54, 0.96 ] 0.99 [ 0.93, 1.00 ]
Ferro 2013 27 0 2 102 0.93 [ 0.77, 0.99 ] 1.00 [ 0.96, 1.00 ]
Hillemann 2009 39 0 7 60 0.85 [ 0.71, 0.94 ] 1.00 [ 0.94, 1.00 ]
Huang 2011 16 0 3 215 0.84 [ 0.60, 0.97 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 37 4 9 130 0.80 [ 0.66, 0.91 ] 0.97 [ 0.93, 0.99 ]
Miotto 2012 58 2 7 107 0.89 [ 0.79, 0.96 ] 0.98 [ 0.94, 1.00 ]
van Ingen 2010 6 0 0 21 1.00 [ 0.54, 1.00 ] 1.00 [ 0.84, 1.00 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. Indirect, Kn, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 6 Indirect, Kn, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 10 0 3 39 0.77 [ 0.46, 0.95 ] 1.00 [ 0.91, 1.00 ]
Ferro 2013 4 0 0 18 1.00 [ 0.40, 1.00 ] 1.00 [ 0.81, 1.00 ]
Huang 2011 16 0 21 197 0.43 [ 0.27, 0.61 ] 1.00 [ 0.98, 1.00 ]
Ignatyeva 2012 37 4 50 89 0.43 [ 0.32, 0.54 ] 0.96 [ 0.89, 0.99 ]
Jin 2013 55 2 40 164 0.58 [ 0.47, 0.68 ] 0.99 [ 0.96, 1.00 ]
Kiet 2010 5 0 0 57 1.00 [ 0.48, 1.00 ] 1.00 [ 0.94, 1.00 ]
Lacoma 2012 5 3 0 19 1.00 [ 0.48, 1.00 ] 0.86 [ 0.65, 0.97 ]
Miotto 2012 56 2 19 95 0.75 [ 0.63, 0.84 ] 0.98 [ 0.93, 1.00 ]
Said 2012 7 4 21 300 0.25 [ 0.11, 0.45 ] 0.99 [ 0.97, 1.00 ]
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Test 7. Indirect, Cm, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 7 Indirect, Cm, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 9 1 2 40 0.82 [ 0.48, 0.98 ] 0.98 [ 0.87, 1.00 ]
Hillemann 2009 39 1 6 60 0.87 [ 0.73, 0.95 ] 0.98 [ 0.91, 1.00 ]
Huang 2011 10 6 4 214 0.71 [ 0.42, 0.92 ] 0.97 [ 0.94, 0.99 ]
Ignatyeva 2012 34 7 5 134 0.87 [ 0.73, 0.96 ] 0.95 [ 0.90, 0.98 ]
Jin 2013 49 8 75 129 0.40 [ 0.31, 0.49 ] 0.94 [ 0.89, 0.97 ]
Lacoma 2012 5 3 0 19 1.00 [ 0.48, 1.00 ] 0.86 [ 0.65, 0.97 ]
Miotto 2012 49 9 9 101 0.84 [ 0.73, 0.93 ] 0.92 [ 0.85, 0.96 ]
Said 2012 7 4 26 295 0.21 [ 0.09, 0.39 ] 0.99 [ 0.97, 1.00 ]
van Ingen 2010 5 1 0 21 1.00 [ 0.48, 1.00 ] 0.95 [ 0.77, 1.00 ]
Zivanovic 2012 4 0 0 15 1.00 [ 0.40, 1.00 ] 1.00 [ 0.78, 1.00 ]
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Test 8. Indirect, XDR, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 8 Indirect, XDR, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chikamatsu 2012 9 0 4 33 0.69 [ 0.39, 0.91 ] 1.00 [ 0.89, 1.00 ]
Hillemann 2009 10 0 4 92 0.71 [ 0.42, 0.92 ] 1.00 [ 0.96, 1.00 ]
Ignatyeva 2012 8 6 32 134 0.20 [ 0.09, 0.36 ] 0.96 [ 0.91, 0.98 ]
Jin 2013 46 4 37 174 0.55 [ 0.44, 0.66 ] 0.98 [ 0.94, 0.99 ]
Kiet 2010 3 0 0 62 1.00 [ 0.29, 1.00 ] 1.00 [ 0.94, 1.00 ]
Miotto 2012 8 6 5 155 0.62 [ 0.32, 0.86 ] 0.96 [ 0.92, 0.99 ]
van Ingen 2010 4 0 0 25 1.00 [ 0.40, 1.00 ] 1.00 [ 0.86, 1.00 ]
Zivanovic 2012 3 0 0 16 1.00 [ 0.29, 1.00 ] 1.00 [ 0.79, 1.00 ]
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Test 9. Indirect, FQ, sequencing.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 9 Indirect, FQ, sequencing
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 22 0 4 26 0.85 [ 0.65, 0.96 ] 1.00 [ 0.87, 1.00 ]
Chikamatsu 2012 17 0 0 29 1.00 [ 0.80, 1.00 ] 1.00 [ 0.88, 1.00 ]
Hillemann 2009 29 0 0 77 1.00 [ 0.88, 1.00 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 0 171 1.00 [ 0.94, 1.00 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 110 12 5 134 0.96 [ 0.90, 0.99 ] 0.92 [ 0.86, 0.96 ]
Miotto 2012 39 4 0 131 1.00 [ 0.91, 1.00 ] 0.97 [ 0.93, 0.99 ]
Surcouf 2011 14 0 0 87 1.00 [ 0.77, 1.00 ] 1.00 [ 0.96, 1.00 ]
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Test 10. Indirect, SLID, sequencing.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 10 Indirect, SLID, sequencing
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 10 0 4 38 0.71 [ 0.42, 0.92 ] 1.00 [ 0.91, 1.00 ]
Chikamatsu 2012 10 0 0 36 1.00 [ 0.69, 1.00 ] 1.00 [ 0.90, 1.00 ]
Hillemann 2009 40 0 0 66 1.00 [ 0.91, 1.00 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 16 0 10 208 0.62 [ 0.41, 0.80 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 49 8 1 203 0.98 [ 0.89, 1.00 ] 0.96 [ 0.93, 0.98 ]
Miotto 2012 58 2 0 114 1.00 [ 0.94, 1.00 ] 0.98 [ 0.94, 1.00 ]
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Test 11. Indirect, XDR, sequencing.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 11 Indirect, XDR, sequencing
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hillemann 2009 14 0 0 92 1.00 [ 0.77, 1.00 ] 1.00 [ 0.96, 1.00 ]
Jin 2013 40 10 0 211 1.00 [ 0.91, 1.00 ] 0.95 [ 0.92, 0.98 ]
Miotto 2012 12 2 0 160 1.00 [ 0.74, 1.00 ] 0.99 [ 0.96, 1.00 ]
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Test 12. Indirect, FQ, sequencing and culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 12 Indirect, FQ, sequencing and culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 22 0 4 26 0.85 [ 0.65, 0.96 ] 1.00 [ 0.87, 1.00 ]
Hillemann 2009 29 0 3 74 0.91 [ 0.75, 0.98 ] 1.00 [ 0.95, 1.00 ]
Huang 2011 63 0 11 160 0.85 [ 0.75, 0.92 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 121 1 26 113 0.82 [ 0.75, 0.88 ] 0.99 [ 0.95, 1.00 ]
Kontsevaya 2011 25 0 4 19 0.86 [ 0.68, 0.96 ] 1.00 [ 0.82, 1.00 ]
Miotto 2012 42 1 15 116 0.74 [ 0.60, 0.84 ] 0.99 [ 0.95, 1.00 ]
Said 2012 33 0 11 292 0.75 [ 0.60, 0.87 ] 1.00 [ 0.99, 1.00 ]
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Test 13. Indirect, SLID, sequencing and culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 13 Indirect, SLID, sequencing and culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Brossier 2010 10 0 4 38 0.71 [ 0.42, 0.92 ] 1.00 [ 0.91, 1.00 ]
Hillemann 2009 39 0 7 60 0.85 [ 0.71, 0.94 ] 1.00 [ 0.94, 1.00 ]
Huang 2011 16 0 21 197 0.43 [ 0.27, 0.61 ] 1.00 [ 0.98, 1.00 ]
Jin 2013 56 1 41 163 0.58 [ 0.47, 0.68 ] 0.99 [ 0.97, 1.00 ]
Miotto 2012 59 0 25 90 0.70 [ 0.59, 0.80 ] 1.00 [ 0.96, 1.00 ]
Said 2012 11 0 21 300 0.34 [ 0.19, 0.53 ] 1.00 [ 0.99, 1.00 ]
Surcouf 2011 11 0 26 295 0.30 [ 0.16, 0.47 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
95The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 14. Indirect, XDR, sequencing and culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 14 Indirect, XDR, sequencing and culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jin 2013 48 2 37 174 0.56 [ 0.45, 0.67 ] 0.99 [ 0.96, 1.00 ]
Miotto 2012 12 2 5 155 0.71 [ 0.44, 0.90 ] 0.99 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. Indirect, FQ, culture followed by sequencing of discrepants.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 15 Indirect, FQ, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kiet 2010 31 0 0 31 1.00 [ 0.89, 1.00 ] 1.00 [ 0.89, 1.00 ]
Lacoma 2012 8 1 3 17 0.73 [ 0.39, 0.94 ] 0.94 [ 0.73, 1.00 ]
Lopez-Roa 2012 33 0 11 292 0.75 [ 0.60, 0.87 ] 1.00 [ 0.99, 1.00 ]
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Test 16. Indirect, SLID, culture followed by sequencing of discrepants.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 16 Indirect, SLID, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jin 2013 56 1 40 163 0.58 [ 0.48, 0.68 ] 0.99 [ 0.97, 1.00 ]
Lacoma 2012 7 1 0 19 1.00 [ 0.59, 1.00 ] 0.95 [ 0.75, 1.00 ]
Said 2012 11 0 21 300 0.34 [ 0.19, 0.53 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. Direct, FQ, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 17 Direct, FQ, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 9 64 0.91 [ 0.84, 0.96 ] 0.98 [ 0.92, 1.00 ]
Barnard 2012 49 9 5 453 0.91 [ 0.80, 0.97 ] 0.98 [ 0.96, 0.99 ]
Hillemann 2009 8 0 1 41 0.89 [ 0.52, 1.00 ] 1.00 [ 0.91, 1.00 ]
Kontsevaya 2013 15 2 12 61 0.56 [ 0.35, 0.75 ] 0.97 [ 0.89, 1.00 ]
Lacoma 2012 1 1 1 10 0.50 [ 0.01, 0.99 ] 0.91 [ 0.59, 1.00 ]
Miotto 2012 7 0 0 49 1.00 [ 0.59, 1.00 ] 1.00 [ 0.93, 1.00 ]
Tukvadze 2014 21 1 5 111 0.81 [ 0.61, 0.93 ] 0.99 [ 0.95, 1.00 ]
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Test 18. Direct, Ofl, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 18 Direct, Ofl, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barnard 2012 49 9 5 453 0.91 [ 0.80, 0.97 ] 0.98 [ 0.96, 0.99 ]
Hillemann 2009 8 0 1 41 0.89 [ 0.52, 1.00 ] 1.00 [ 0.91, 1.00 ]
Miotto 2012 7 0 0 49 1.00 [ 0.59, 1.00 ] 1.00 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. Direct, SLID, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 19 Direct, SLID, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Barnard 2012 43 3 0 470 1.00 [ 0.92, 1.00 ] 0.99 [ 0.98, 1.00 ]
Kontsevaya 2013 6 0 59 12 0.09 [ 0.03, 0.19 ] 1.00 [ 0.74, 1.00 ]
Lacoma 2012 3 3 0 6 1.00 [ 0.29, 1.00 ] 0.67 [ 0.30, 0.93 ]
Miotto 2012 7 5 1 41 0.88 [ 0.47, 1.00 ] 0.89 [ 0.76, 0.96 ]
Tukvadze 2014 19 1 47 71 0.29 [ 0.18, 0.41 ] 0.99 [ 0.93, 1.00 ]
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Test 20. Direct, Ak, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 20 Direct, Ak, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Barnard 2012 43 3 0 470 1.00 [ 0.92, 1.00 ] 0.99 [ 0.98, 1.00 ]
Kontsevaya 2013 7 0 4 72 0.64 [ 0.31, 0.89 ] 1.00 [ 0.95, 1.00 ]
Miotto 2012 6 5 1 42 0.86 [ 0.42, 1.00 ] 0.89 [ 0.77, 0.96 ]
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Test 21. Direct, Kn, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 21 Direct, Kn, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Kontsevaya 2013 6 0 58 12 0.09 [ 0.04, 0.19 ] 1.00 [ 0.74, 1.00 ]
Miotto 2012 7 4 1 42 0.88 [ 0.47, 1.00 ] 0.91 [ 0.79, 0.98 ]
Tukvadze 2014 19 1 47 71 0.29 [ 0.18, 0.41 ] 0.99 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
99The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Test 22. Direct, Cm, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 22 Direct, Cm, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 16 0 6 128 0.73 [ 0.50, 0.89 ] 1.00 [ 0.97, 1.00 ]
Kontsevaya 2013 5 2 2 74 0.71 [ 0.29, 0.96 ] 0.97 [ 0.91, 1.00 ]
Miotto 2012 6 5 0 43 1.00 [ 0.54, 1.00 ] 0.90 [ 0.77, 0.97 ]
Tukvadze 2014 13 7 10 108 0.57 [ 0.34, 0.77 ] 0.94 [ 0.88, 0.98 ]
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Test 23. Direct, XDR, culture.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 23 Direct, XDR, culture
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Barnard 2012 24 2 2 488 0.92 [ 0.75, 0.99 ] 1.00 [ 0.99, 1.00 ]
Kontsevaya 2013 3 0 19 52 0.14 [ 0.03, 0.35 ] 1.00 [ 0.93, 1.00 ]
Miotto 2012 2 3 0 49 1.00 [ 0.16, 1.00 ] 0.94 [ 0.84, 0.99 ]
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Test 24. Direct, FQ, culture followed by sequencing of discrepants.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 24 Direct, FQ, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 96 1 9 64 0.91 [ 0.84, 0.96 ] 0.98 [ 0.92, 1.00 ]
Barnard 2012 54 4 2 455 0.96 [ 0.88, 1.00 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Direct, SLID, culture followed by sequencing of discrepants.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 25 Direct, SLID, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ajbani 2012 22 0 0 128 1.00 [ 0.85, 1.00 ] 1.00 [ 0.97, 1.00 ]
Barnard 2012 44 2 0 470 1.00 [ 0.92, 1.00 ] 1.00 [ 0.98, 1.00 ]
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Test 26. Direct, XDR, culture followed by sequencing of discrepants.
Review: The diagnostic accuracy of the GenoType MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs
Test: 26 Direct, XDR, culture followed by sequencing of discrepants
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Miotto 2012 24 2 2 488 0.92 [ 0.75, 0.99 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S





Culture, n/N (%) Genetic testing, n/N (%) Genetic and culture test-
ing, n/N (%)
Culture followed by ge-
netic testing of discor-
dant results, n/N (%)
Fluoroquinolones 16/16 (100)† 7/16 (44) 7/16 (44) 3/16 (19)
Ofloxacin 11/16 (69) 0 0 0
Moxifloxacin 4/16 (25) 0 0 0
Levofloxacin 1/16 (6) 0 0 0
Second-line injectable
drugs
14/14 (100)† 6/14 (43) 7/14 (50) 3/14 (21)
Amikacin 9/14 (64) 0 0 0
Kanamycin 8/14 (57) 0 0 0
Capreomycin 10/14 (71) 0 0 0
XDR-TB 8/8 (100) 3/8 (38) 2/8 (25) 0
†A total of 16 and 14 studies were included that evaluated MTBDRsl against a fluoroquinolone and a second-line injectable drug,
culture reference standard. These form the denominators to generate percentages of these studies that included a particular additional
reference standard.
102The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.





Culture, n/N (%) Genetic testing, n/N (%) Genetic and culture test-
ing, n/N (%)
Culture followed by ge-
netic testing of discor-
dant results, n/N (%)
Fluoroquinolones 7/7 (100)† 0 0 2/7 (29)
Ofloxacin 3/7 (43) 0 0 1/7 (14)
Second-line injectable
drugs
6/6 (100)† 0 0 2/5 (40)
Amikacin 4/6 (67) 0 0 1/6 (17)
Kanamycin 4/6 (67) 0 0 0
Capreomycin 6/6 (100) 0 0 0
XDR-TB 3/3 (100) 0 0 1/3 (34)
†A total of six and five studies were included that evaluated MTBDRsl against a fluoroquinolone and a second-line injectable drug,
culture reference standard. These form the denominators to generate percentages of these studies that included a particular additional
reference standard.
Table 3. Accuracy of MTBDRsl for detection of resistance to fluoroquinolones and second-line injectable drugs, by reference













Fluoroquinolone, culture, indirect test-
ing
(16 studies, 1766 participants)
Fluoroquinolone, culture, direct testing
(7 studies, 1033 participants)
83.1% (78.7 to 86.
7)
97.7% (94.3 to 99.
1)
85.1% (71.9 to 92.
7)
98.2% (96.8 to 99.
0)
0.670 0.293
Fluoroquinolone, culture, indirect test-
ing
(16 studies, 1766 participants)
Fluoroquinolone, genetic sequencing,
indirect testing
(7 studies, 974 participants)
83.1% (78.7 to 86.
7)
97.7 (94.3 to 99.1) 99.3%(85.9 to 100) 99.7%(92.0 to 100) < 0.001 0.663
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Table 3. Accuracy of MTBDRsl for detection of resistance to fluoroquinolones and second-line injectable drugs, by reference
standard and type of testing, indirect comparisons (Continued)
Fluoroquinolone, culture, indirect test-
ing
(16 studies, 1766 participants)
Fluoroquinolone, genetic sequencing
and culture, indirect testing
(7 studies, 1211 participants)
83.1% (78.7 to 86.
7)
97.7% (94.3 to 99.
1)
82.0 (77.7 to 85.6) 99.8 (98.5 to 100) 0.983 < 0.001
Ofloxacin, culture, indirect testing
(11 studies, 1544 participants)
Moxifloxacin, culture, indirect testing
(4 studies, 222 participants)
82.9% (79.5, 85.9) 98.2% (96.1, 99.1) 91.4% (64.7 to 98.
4)
90.6% (79.3 to 96.
1)
0.239 0.061
Second-line injectable drugs, culture, in-
direct testing
(14 studies, 1637 participants)
Second-line injectable drugs, culture, di-
rect testing
(6 studies, 947 participants)
76.9% (61.1 to 87.
6)
99.5% (97.1 to 99.
9)
94.4% (25.2 to 99.
9)
98.2% (88.9 to 99.
7)
0.451 0.005
Second-line injectable drugs, culture, in-
direct testing
(14 studies, 1637 participants)
Second-line injectable drugs, indirect,
genetic sequencing
(6 studies, 873 participants)
76.9% (61.1 to 87.
6)
99.5% (97.1 to 99.
9)
97.0% (77.0 to 99.
7)
99.5%(94.5 to 100) 0.047* 0.935*
Second-line injectable drugs, culture, in-
direct testing
(14 studies, 1637 participants)
Second-line injectable drugs, genetic se-
quencing and culture, indirect testing
(7 studies, 1491 participants)
76.9% (61.1 to 87.
6)
99.5%(97.1 to 100) 56.7% (40.8 to 71.
3)
99.9%(99.2 to 100) 0.340 0.003
Amikacin, indirect, culture
(9 studies, 1017 participants)
Kanamycin, culture, indirect testing
(9 studies, 1342 participants)
87.9% (82.1 to 92.
0)
99.5% (97.5 to 99.
9)
66.9% (44.1 to 83.
8)
98.6% (96.1 to 99.
5)
0.006 0.262
Amikacin, culture, indirect testing
(9 studies, 1017 participants)
Capreomycin, culture, indirect testing
(10 studies, 1406 participants)
87.9% (82.1 to 92.
0)
99.5% (0.975 to 0.
999)
79.5% (58.3 to 91.
4)
95.8% (93.4 to 97.
3)
0.309* 0.003*
Kanamycin, culture, indirect testing
(9 studies, 1342 participants)
Capreomycin, culture, indirect testing
(10 studies, 1406 participants)
104The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 3. Accuracy of MTBDRsl for detection of resistance to fluoroquinolones and second-line injectable drugs, by reference
standard and type of testing, indirect comparisons (Continued)
66.9% (44.1 to 83.
8)
98.6% (96.1 to 99.
5)
79.5% (58.3 to 91.
4)
95.8% (93.4 to 97.
3)
0.437 0.043
Amikacin, culture, indirect testing
(9 studies, 1017 participants)
Amikacin, culture, direct testing
(4 studies, 803 participants)
87.9% (82.1 to 92.
0)
99.5% (0.975 to 0.
999)
97.3% (55.1 to 99.
9)
99.3% (92.3 to 99.
9)
0.739 0.035
An indirect comparison uses all studies. Indirect statistical comparisons for the purpose of determining pooled accuracy estimates are
not to be confused with indirect MTBDRsl testing which involves testing of the culture isolate.
*Indicates the model allowed the variances of the random effects to be associated with the covariate.
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
Table 4. Accuracy of MTBDRsl for detection of resistance to fluoroquinolones and second-line injectable drugs, by reference













Fluoroquinolone, culture, indirect test-
ing
(6 studies, 873 participants)
Fluoroquinolone, genetic sequencing,
indirect testing
(6 studies, 873 participants)
82.4% (77.6 to 86.
3)
98.8% (94.3 to 99.
8)
99.3%(81.2 to 100) 99.3%(90.8 to 100) < 0.001 0.971
Fluoroquinolone, culture, indirect test-
ing
(7 studies, 1211 participants)
Fluoroquinolone, genetic sequencing
and culture, indirect testing
(7 studies, 1211 participants)
81.8% (77.2 to 85.
7)
99.0% (95.0 to 99.
8)
82.0% (77.7 to 85.
6)
99.8%(98.5 to 100) 0.795 < 0.001
Second-line injectable drugs, culture, in-
direct testing
(6 studies, 873 participants)
Second-line injectable drugs, genetic se-
quencing, indirect testing
(6 studies, 873 participants)
74.6% (66.2 to 81.
5)
99.9%(71.8 to 100) 97.0% (77.0 to 99.
7)
99.5%(94.5 to 100) 0.053* 0.349*
Second-line injectable drugs, culture, in-
direct testing
(6 studies, 1159 participants)
Second-line injectable drugs, genetic se-
quencing and culture, indirect testing
(6 studies, 1159 participants)
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Table 4. Accuracy of MTBDRsl for detection of resistance to fluoroquinolones and second-line injectable drugs, by reference
standard and type of testing, direct comparisons (Continued)
70.5% (52.0 to 84.
1)
99.8%(93.8 to 100) 61.3% (45.8 to 74.
8%)
99.9%(99.0 to 100) 0.729 0.015
Amikacin, culture, indirect testing
(6 studies, 618 participants)
Capreomycin, culture, indirect testing
(6 studies, 618 participants)
87.1% (77.0 to 93.
1)
99.9%(80.8 to 100) 85.6% (78.0 to 90.
9)
96.8% (94.8 to 98.
0)
0.989 0.029
Kanamycin, culture, indirect testing
(6 studies, 1086 participants)
Capreomycin, culture, indirect testing
(6 studies, 1086 participants)
54.3% (34.5 to 72.
8)
98.3% (94.8 to 99.
5)
69.7% (38.0 to 89.
6)
96.1% (93.3 to 97.
8)
0.594 0.188
A direct comparison uses only studies that directly compared the two evaluations. Direct statistical comparisons for the purpose of
determining pooled accuracy estimates are not to be confused with direct testing that pertains to the method for testing with
MTBDRsl.
*Indicates the model allowed the variances of the random effects to be associated with the covariate.
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
Table 5. Accuracy of MTBDRsl for detection of extensively drug-resistant TB, by reference standard and type of testing, direct
comparisons
Type of testing Number of participants
(studies)







Indirect 880 (8 studies) 173 70.9% (42.9 to 88.8) 98.8% (96.1, 99.6)
Direct 644 (3 studies) 50 * *
Genetic testing
Indirect 541 (3 studies) 66 100.0% (94.6 to 100.0)‡ 97.5% (95.6 to 98.7)‡
Direct 0 (0 studies) 0 Not applicable Not applicable
Genetic and culture testing
Indirect 435 (2 studies) 102 58.8% (49.1 to 67.9) 98.8% (96.8 to 99.5)
Direct 0 (0 studies) 0 Not applicable Not applicable
Culture followed by genetic testing of discordant results
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Table 5. Accuracy of MTBDRsl for detection of extensively drug-resistant TB, by reference standard and type of testing, direct
comparisons (Continued)
Indirect 0 (0 studies) 0 Not applicable Not applicable
Direct 516 (1 study) 26 92.3% (74.9 to 99.1) 99.6% (98.5 to 100.0)
*We observed considerable heterogeneity and did not pool results.
‡We observed little heterogeneity and determined summary estimates of sensitivity and specificity separately using a fixed-effect model.
TP = true positive; FN = false negative.
Table 6. Sensitivity analyses for the fluoroquinolones















All studies of fluoroquinolones
1766 (16 studies) 83.1% (78.7 to 86.
7)
97.7% (94.3 to 99.
1)
1033 (7 studies) 85.1% (71.9 to 92.
7)
98.2% (96.8 to 99.
0)
Consecutive or random sampling
1493 (10 studies) 81.5% (77.8 to 84.
8)
98.5% (94.0 to 99.
6)
504 (5 studies) 85.6% (68.1 to 94.
3)
99.0% (96.4 to 99.
8)
Cross-sectional studies
1166 (10 studies) 83.3% (77.1 to 88.
1)
96.8% (91.0 to 98.
9)
927 (5 studies) 82.0% (65.7 to 91.
6)
98.0% (96.7 to 98.
8)
Index test results blinded to reference standard results
1307 (9 studies) 81.2% (77.0 to 84.
8)
98.1% (92.1 to 99.
6)
845 (5 studies) 85.1% (64.2 to 94.
8)
97.8% (95.8 to 98.
9)
Reference standard results blinded to index test results
1104 (8 studies) 78.6% (73.3 to 83.
1)
96.9% (93.4 to 98.
6)
742 (3 studies) 91.6 (86.3 to 94.9) 98.3 (96.8 to 99.1)
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Table 7. Sensitivity analyses for the second-line injectable drugs















All studies of second-line injectable drugs
1637 (14 studies) 76.9% (61.1 to 87.
6)
99.5% (97.1 to 99.
9)
947 (6 studies) 94.4% (25.2 to 99.
9)
98.2% (88.9 to 99.
7)
Consecutive or random sampling
1391 (9 studies) 76.5% (53.8 to 90.
1)
99.7% (95.9 to 100.
0)
419 (4 studies) 71.9% (9.6 to 98.4) 98.9% (87.4 to 99.
9)
Cross-sectional studies
1035 (8 studies) 77.0% (51.5 to 91.
3)
98.7% (94.7 to 99.
7)
893 (5 studies) 99.2% (0.5 to 100.
0)
99.1% (90.7 to 99.
9)
Index test results blinded to reference standard results
1255 (8 studies) 74.3 (46.9 to 90.4) 98.9 (94.6 to 99.8) 809 (5 studies) 98.6% (12.7 to 100.
0)
98.1% (81.7 to 99.
8)
Reference standard results blinded to index test results
1102 (8 studies) 70.4% (42.7 to 88.
4)
99.2% (94.7 to 99.
9)
720 (3 studies) 99.0% (79.7 to 100.
0)
98.9% (89.6 to 100.
0)
A P P E N D I C E S
Appendix 1. The manufacturer-supplied result template
Figure 15 is an example of the manufacturer supplied result template.
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Figure 15. An example of the manufacturer-supplied result template.
109The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Appendix 2. Readout from an automated strip reader
Figure 16 is an example of a readout from an automated strip reader. The results are generated automatically and validated manually
by a technician.
Figure 16. An example of a readout from an automated strip reader. The results are generated
automatically and validated manually by a technician.
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4. exp Tuberculosis, Pulmonary/







12. 3 and 11
EMBASE (OVID)
1. tuberculosis.mp. or lung tuberculosis/ or Mycobacterium tuberculosis/ or multidrug resistant tuberculosis/
2. (MDR-TB or XDR-TB).mp.
3. exp Mycobacterium tuberculosis/
4. 1 or 2 or 3
5. (MTBDR* or “Genotype MTBDR*”).mp
6. 4 and 5
Web of Knowledge (SCI-expanded, Conference Proceedings science) and BIOSIS previews
Topic=(MTBDR*) AND Topic=(tuberculosis OR TB OR MDR-TB OR XDR-TB)
LILACS
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) (Words) AND (MTBDR$) (Wor
SCOPUS
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB ) (title, abstract, keywords) AND (MTBDR*) (title, abstract,
keywords)
CIDG Specialized register
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) AND (MTBDR*)
ProQuest Dissertations & Theses A&I search strategy
ab(tuberculosis) AND ab((diagnostic test* OR RDT* OR MTBDR*))
Medion
MTBDR* (title or abstract)
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metaRegister of Controlled Trials (mRCT)
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) AND (MTBDR*)
WHO International Clinical Trials Registry Platform
(tuberculosis OR TB OR mycobacterium OR MDR-TB OR XDR-TB) AND (MTBDR*)
Appendix 4. QUADAS-2 rules and interpretation
We use “patients” below with the understanding that studies in this Cochrane Review may be evaluating patient specimens.
Domain 1: Patient selection
Risk of bias: Could the selection of patients have introduced bias?
Signaling question 1: Was a consecutive or random sample of patients enrolled?
We will score ’yes’ if the study enrolled a consecutive or random sample of eligible patients; ’no’ if the study selected patients by
convenience; and ’unclear’ if the study did not report the manner of patient selection or was not clearly reported.
Signaling question 2: Was a case-control design avoided?
We will score ’yes’ if the study enrolled only TB patients with suspected resistance to second-line drugs, including patients with
confirmed MDR-TB; ’no’ if the study enrolled TB patients with confirmed resistance to second-line drugs; and ’unclear’ for all other
scenarios or if it was not clearly reported.
Signaling question 3: Did the study avoid inappropriate exclusions?
An inappropriate exclusion might occur if, after the laboratory technician runs the index and reference tests, he or she does not record
the test results in the study. This might occur if there were resource constraints as one might find in practice, but we do not expect
this to occur in the research studies included in this review. We will score ’yes’ for all studies, as we do not anticipate inappropriate
exclusions.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We will judge ’low’ concern if the selected specimens match the review question, which reflects the way the test will be used in practice.
We will judge ’high’ concern if the selected specimens or isolates do not represent those for which the test will be used in practice, such
as in individuals who are not suspected of having DR-TB. We will judge ’unclear’ concern if we cannot tell.
Domain 2: Index test
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Signaling question 1: Were the index test results interpreted without knowledge of the results of the reference standard?
We will score this question ’yes’ if the reader of the assay was blinded to results of reference tests. We will score ’no’ if the reader of
the assay was not blinded to the results of reference tests. If the specimens were from a biobank comprised of specimens with known
second-line drug resistance and the identity of these specimens was known to the assay reader, we will also answer ’no’. We will score
’unclear’ if it was not stated in the paper or if the authors failed to answer this question.
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Signaling question 2: If a threshold was used, was it prespecified?
A threshold is prespecified in all versions of MTBDRsl. We will answer this question ’yes’ for all studies.
Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question?
Variations in test technology, execution or interpretation may affect estimates of the diagnostic accuracy of a test. However, we will
judge these issues to be of ’low’ concern for all studies in this review, as the MTBDRsl assay is standardized.
Domain 3: Reference standard
Risk of bias: Could the reference standard, its conduct or its interpretation have introduced bias?
Signaling question 1: Is the reference standard likely to correctly classify the target condition?
Culture-based DST is not 100% accurate for detection of drug resistance, especially resistance to second-line drugs. However, it is the
test currently endorsed by WHO when performed using WHO-recommended critical drug concentrations. Therefore, for culture-
based DST, we will answer ’yes’ if WHO critical concentrations were used, ’no’ if they were not used and ’unclear’ if the study authors
do not specify.
Genetic sequencing (gene sequencing of loci known to be associated with drug resistance) is considered by researchers in this field to
be the best reference standard for testing for the presence of drug resistance. Although sequencing may not be performed for all regions
of the TB genome associated with resistance, we consider this to be a concern about the setting in which the test is applied, rather than
a concern about risk of bias.
We will answer ’yes’ when sequencing, culture and sequencing, and culture followed by discrepant sequencing are used.
Signaling question 2: Were the reference standard results interpreted without knowledge of the results of the index test?
We will score ’yes’ if the reference test provided an automated result (for example, MGIT 960 DST), blinding was explicitly stated,
or it was clear that the reference test was performed at a separate laboratory, or performed by different people, or both. We will score
’no’ if the study stated that the reference standard result was interpreted with knowledge of the MTBDRsl assay result. We will score
’unclear’ if it was not stated in the paper or if the authors failed to answer this question.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question?
We judge applicability to be of ’low concern’ for all studies unless studies used genetic sequencing only and did not look at known
resistance determining regions outside of gyrA for FQ resistance and outside of rrs for SLID resistance, in which case we will answer
’unclear risk’.
Domain 4: Flow and timing
Risk of bias: Could the patient flow have introduced bias?
Signaling question 1: Was there an appropriate interval between the index test and reference standard?
We expect the reference standard test to be undertaken at the same time as the index test (ie each performed on a paired sample for
the majority of studies). However, we expect some studies to include specimens from patients who have received a reference test on an
earlier sample. The sample applies to some culture isolates, whose drug susceptibility profile might have been confirmed prior to the
index test being available. We will answer ’yes’ if the tests were paired or were separated by a few days. We will answer ’no’ if reference
and index tests were not done on paired samples and were separated by several months. As patients suspected of second-line drug
resistance are often on some form of anti-TB therapy, it is possible that variation in the microbial population of specimens collected at
different timepoints may occur. We will score ’unclear’ if it was not stated in the paper or if the authors failed to answer this question.
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Signaling question 2: Did all patients receive the same reference standard?
We will answer ’yes’ if the same reference standard was applied to all patients or a random sample of patients, ’no’ if the reference
standard was only applied to a selective group of patients and ’unclear’ if it was not stated in the paper or if the authors failed to answer
this question. We will answer ’no’ when culture followed by genetic sequencing of the discrepant results was used as the reference
standard because there is potential for verification bias when the same reference standard is not being used to confirm all index test
results. Concerning genetic sequencing as the reference standard, the selective use of this method to resolve discordant results may be
done because of the technical aspects, costs and time associated. For the reference standard ‘genetic sequencing followed culture’, we
will answer ’no’ for all studies.
Signaling question 3: Were all patients included in the analysis?
We will determine the answer to this question by comparing the number of participants enrolled with the number of patients included
in the two-by-two tables. We will note if the authors report the number of indeterminate assay results.
We will score ’yes’ if the number of participants enrolled was clearly stated and corresponded to the number presented in the analysis
or if exclusions were adequately described. We will score ’no’ if there were participants missing or excluded from the analysis and there
was no explanation given. We will score ’unclear’ if not enough information was given to assess whether participants were excluded
from the analysis.
Appendix 5. Fluoroquinolone resistance, different reference standards
Figure 17 shows forest plots of MTBDRsl sensitivity and specificity for fluoroquinolone (FQ) resistance detection when performed
indirectly using different reference standards. The individual studies are ordered by decreasing sensitivity. TP = true positive; FP = false
positive; FN = false negative; TN = true negative. Values between brackets are the 95% CIs of sensitivity and specificity. The figure
shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
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Figure 17. Forest plots of MTBDRsl sensitivity and specificity for fluoroquinolone (FQ) resistance detection
when performed indirectly using different reference standards. The individual studies are ordered by
decreasing sensitivity. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values
between brackets are the 95% CIs of sensitivity and specificity. The figure shows the estimated sensitivity and
specificity of the study (blue square) and its 95% CI (black horizontal line).
Appendix 6. Fluoroquinolone resistance, individual drugs, indirect testing
Figure 18 shows forest plots of MTBDRsl sensitivity and specificity for ofloxacin (Ofl) and moxifloxacin (Mx) resistance detection
when performed indirectly and using phenotypic culture-based DST as a reference standard. The individual studies are ordered by
decreasing sensitivity. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the
95% CIs of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95%
CI (black horizontal line).
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Figure 18. Forest plots of MTBDRsl sensitivity and specificity for ofloxacin (Ofl) and moxifloxacin (Mx)
resistance detection when performed indirectly and using phenotypic culture-based DST as a reference
standard. The individual studies are ordered by decreasing sensitivity. TP = true positive; FP = false positive;
FN = false negative; TN = true negative. Values between brackets are the 95% CIs of sensitivity and specificity.
The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black
horizontal line).
Appendix 7. Summary plot, fluoroquinolone resistance, individual drugs
Figure 19 shows summary plots of MTBDRsl sensitivity and specificity comparing detection of resistance for ofloxacin (Ofl) and
moxifloxacin (Mx). The solid circles correspond to the summary estimates of sensitivity and specificity and are shown with 95%
confidence regions (dotted lines) and 95% prediction regions (dashed lines).
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Figure 19. Summary plots of MTBDRsl sensitivity and specificity comparing direct detection of resistance
for ofloxacin (Ofl) and moxifloxacin (Mx) using culture as a reference standard. The solid circles correspond to
the summary estimates of sensitivity and specificity and are shown with 95% confidence regions (dotted lines)
and 95% prediction regions (dashed lines).
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Appendix 8. MTBDRsl pooled accuracy estimates for the detection of resistance to second-line
injectable drugs (when MTBDRsl testing was performed directly and indirectly) with Kontsevaya




Second-line injectable drug, cul-
ture, indirect

























Indirect comparisons for the purpose of determining pooled accuracy estimates are not to be confused with indirect testing that pertains
to the method for testing with MTBDRsl..
1Likelihood ratio test for evidence of a significant difference between accuracy estimates.
Appendix 9. Second-line injectable drug resistance, different reference standards
Figure 20 shows forest plots of MTBDRsl sensitivity and specificity when performed indirectly for second-line injectable drug (SLID)
resistance detection and using three different reference standards. The individual studies are ordered by decreasing sensitivity. TP =
true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% CIs of sensitivity and
specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
118The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 20. Forest plots of MTBDRsl sensitivity and specificity when performed indirectly for second-line
injectable drug (SLID) resistance detection and using three different reference standards. The individual
studies are ordered by decreasing sensitivity. TP = true positive; FP = false positive; FN = false negative; TN =
true negative. Values between brackets are the 95% CIs of sensitivity and specificity. The figure shows the
estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the Cochrane Review, we added an additional reference standard defined as two reference tests used together: phenotypic culture-
based DST and genetic sequencing of the same samples. We added the question, “Was a case-control design avoided?” to the sensitivity
analyses. We stated in the protocol that we would perform sensitivity analyses for each target condition, using the subset of studies that
provided one result per patient. However, these studies did not provide sufficient data for such analyses. After further consultation with
technical experts, we changed how we assessed risk with regard to the Reference Standard and Flow and Timing Domains of QUADAS-
2. Instead of answering ’unclear’ to Signaling Question 1 of the Reference Standard Domain when culture was used, we decided to
distinguish between studies that used culture with a WHO-recommended critical concentration in order to define resistance (answered
as ’yes’) and those which did not (answered as ’no’) or which did not state a concentration (answered as ’unclear’). We therefore instead
answered ’yes’ if the recommended drug concentration was used. For the Applicability question of this domain, we answered ’unclear’
if genetic sequencing was used in the reference standard and it did not examine genes (gyrb for the FQs and eis for the SLIDs) known
to be associated with resistance. For Signalling Question 2 under the Flow and Timing Domain, we have now explicitly stated that we
answered ’no’ when culture followed by the genetic sequencing of discordant results was performed.
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